U.S. patent application number 16/852136 was filed with the patent office on 2020-10-01 for hinge modified antibody fragments and methods of making.
This patent application is currently assigned to GENENTECH, INC.. The applicant listed for this patent is GENENTECH, INC.. Invention is credited to Hok Seon Kim, Ingrid Kim, Yu-Ju G. Meng, Christoph Spiess.
Application Number | 20200308304 16/852136 |
Document ID | / |
Family ID | 1000004896877 |
Filed Date | 2020-10-01 |
![](/patent/app/20200308304/US20200308304A1-20201001-D00001.png)
![](/patent/app/20200308304/US20200308304A1-20201001-D00002.png)
![](/patent/app/20200308304/US20200308304A1-20201001-D00003.png)
![](/patent/app/20200308304/US20200308304A1-20201001-D00004.png)
![](/patent/app/20200308304/US20200308304A1-20201001-D00005.png)
![](/patent/app/20200308304/US20200308304A1-20201001-D00006.png)
![](/patent/app/20200308304/US20200308304A1-20201001-D00007.png)
![](/patent/app/20200308304/US20200308304A1-20201001-D00008.png)
![](/patent/app/20200308304/US20200308304A1-20201001-D00009.png)
![](/patent/app/20200308304/US20200308304A1-20201001-D00010.png)
![](/patent/app/20200308304/US20200308304A1-20201001-D00011.png)
View All Diagrams
United States Patent
Application |
20200308304 |
Kind Code |
A1 |
Meng; Yu-Ju G. ; et
al. |
October 1, 2020 |
HINGE MODIFIED ANTIBODY FRAGMENTS AND METHODS OF MAKING
Abstract
The instant disclosure provides antibody fragments (e.g., Fab
and F(ab').sub.2) having reduced or no reactivity towards
pre-existing anti-hinge antibodies (AHA) and compositions
comprising such antibody fragments, as well as methods of making
and using such antibody fragments and compositions.
Inventors: |
Meng; Yu-Ju G.; (South San
Francisco, CA) ; Kim; Hok Seon; (South San Francisco,
CA) ; Kim; Ingrid; (South San Francisco, CA) ;
Spiess; Christoph; (South San Francisco, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
GENENTECH, INC. |
South San Francisco |
CA |
US |
|
|
Assignee: |
GENENTECH, INC.
South San Francisco
CA
|
Family ID: |
1000004896877 |
Appl. No.: |
16/852136 |
Filed: |
April 17, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15967154 |
Apr 30, 2018 |
10662254 |
|
|
16852136 |
|
|
|
|
PCT/US2016/059137 |
Oct 27, 2016 |
|
|
|
15967154 |
|
|
|
|
62346905 |
Jun 7, 2016 |
|
|
|
62248792 |
Oct 30, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 2317/94 20130101;
C07K 2317/52 20130101; C07K 16/4283 20130101; C07K 2317/34
20130101; C07K 2317/53 20130101; C07K 2317/75 20130101; C07K
2317/71 20130101; C07K 2317/54 20130101; C07K 2317/76 20130101;
C07K 2317/55 20130101 |
International
Class: |
C07K 16/42 20060101
C07K016/42 |
Claims
1. A composition comprising an isolated Fab antibody fragment,
wherein the Fab antibody fragment has reduced or no reactivity
towards pre-existing anti-hinge antibodies.
2. The composition of claim 1, wherein the Fab antibody fragment is
an IgG1 Fab.
3. The composition of claim 2, wherein the IgG1 Fab terminates with
residue D.sub.221.
4. The composition of claim 2, wherein the IgG1 Fab terminates with
residue K222.
5. The composition of claim 2, wherein the IgG1 Fab comprises a
T225X mutation, wherein X is any amino acid except T.
6. The composition of claim 2, wherein the IgG1 Fab terminates with
amino acids comprising an amino acid sequence selected from the
group consisting of CDKTHT (SEQ ID NO: 4), CDKTHL (SEQ ID NO: 15),
CDKTH (SEQ ID NO: 16), CDKT (SEQ ID NO: 17), CDK and CD.
7. The composition of claim 6, wherein the IgG1 Fab terminates with
amino acids comprising the amino acid sequence CDKTHT (SEQ ID NO:
4)
8. The composition of claim 6, wherein the IgG1 Fab terminates with
amino acids comprising the amino acid sequence CDKTHL (SEQ ID NO:
15).
9. The composition of claim 6, wherein the IgG1 Fab terminates with
amino acids comprising the amino acid sequence CDKTH (SEQ ID NO:
16).
10. The composition of claim 6, wherein the IgG1 Fab terminates
with amino acids comprising the amino acid sequence CDKT (SEQ ID
NO: 17).
11. The composition of claim 6, wherein the IgG1 Fab terminates
with amino acids comprising the amino acid sequence CDK.
12. The composition of claim 6, wherein the IgG1 Fab terminates
with amino acids comprising the amino acid sequence CD.
13. The composition of claim 1, wherein the Fab antibody fragment
is an IgG4 Fab.
14. The composition of claim 13, wherein the IgG4 Fab terminates
with amino acids comprising an amino acid sequence selected from
group consisting of KYGPP (SEQ ID NO: 18), KYGP (SEQ ID NO: 19),
KYG and KY.
15. The composition of claim 14, wherein the IgG4 Fab terminates
with amino acids comprising the amino acid sequence KYGPP (SEQ ID
NO: 18).
16. The composition of claim 14, wherein the IgG4 Fab terminates
with amino acids comprising the amino acid sequence KYGP (SEQ ID
NO: 19).
17. The composition of claim 14, wherein the IgG4 Fab terminates
with amino acids comprising the amino acid sequence KYG.
18. The composition of claim 14, wherein the IgG4 Fab terminates
with amino acids comprising the amino acid sequence KY.
19. The composition of claim 13, wherein the IgG4 Fab terminates
with residue K218.
20. The composition of claim 1, wherein the Fab antibody fragment
comprises a heavy chain constant region that comprises an amino
acid sequence selected from the group consisting of SEQ ID NOs: 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and conservative
modifications of.
21. The composition of claim 1, wherein the Fab antibody fragment
exhibits reduced binding to Fc.gamma.RIIIa, C1q or a combination
thereof.
22. A pharmaceutical formulation comprising the composition of
claim 1 and a pharmaceutically acceptable carrier.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 15/967,154, filed Apr. 30, 2018, which is a
continuation of International Patent Application No.
PCT/US2016/059137, filed Oct. 27, 2016, which claims priority to
U.S. Provisional Patent Application Ser. No. 62/248,792, filed Oct.
30, 2015, and U.S. Provisional Patent Application Ser. No.
62/346,905, filed Jun. 7, 2016, the contents of each of which are
incorporated by reference in their entirety, and to each of which
priority is claimed.
SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which
has been submitted electronically in ASCII format and is hereby
incorporated by reference in its entirety. Said ASCII copy, created
on Apr. 17, 2020, is named 00B206_0908_SL.txt and is 26,245 bytes
in size.
FIELD OF THE INVENTION
[0003] The present disclosure relates to antibody fragments (e.g.,
Fab and F(ab').sub.2) having reduced or no reactivity towards
pre-existing anti-hinge antibodies (AHA) and compositions
comprising such antibody fragments, as well as methods of making
and using such antibody fragments and compositions.
BACKGROUND
[0004] Antibodies are composed of two Fab regions that are
connected by a flexible hinge-region to the Fc. While the Fab
mediates recognition and binding of the antigen, two important
functions of the Fc are to mediate effector function by engagement
with Fcy receptors (1) and to confer long serum half-life by
binding to the salvage receptor, FcRn (2). In particular, the slow
pharmacokinetics of IgG contribute to the success of antibodies as
therapeutics as it enables less frequent dosing compared to other
biotherapeutics. Consequently, the majority of approved therapeutic
antibodies have full-length IgG format. Unlike IgG, the serum
half-life of an isolated Fab fragment is short (3) and such
property is required for indications when short plasma half-life is
desired as with three FDA approved Fab molecules (4). One
therapeutic Fab molecule directed against platelet surface receptor
GPIIb/IIIa (abciximab, REOPRO.RTM.) is commercially produced by
proteolytic cleavage with papain (5), which is the original method
of Fab production (6). With the advances in molecular cloning,
recombinant expression of antibody fragments has become an
attractive route to generate Fab molecules as exemplified by the
second approved Fab therapeutic, anti-VEGF (ranibizumab,
Lucentis.RTM.) (7) and the recently approved Fab against dabigatran
(idarucizumab, Praxbind.RTM.) (33). Fab molecules are advantageous,
for example, when transient systemic activity that does not persist
past dosing is desired or when administration and activity are
localized to a peripheral compartment such as the eye.
[0005] Many proteases against the antibody hinge region have been
implicated as the mechanism by which pathogens and tumor cells
attempt to evade the host immune response (13). Resulting
C-terminal neoepitopes, however, are eventually recognized by the
immune system and anti-hinge antibodies (AHA) are generated. Such
autoantibodies to the upper-hinge region of the Fab and the
lower-hinge region of the F(ab').sub.2 have been shown in several
studies (17-21). These pre-existing AHA titers vary from donor to
donor (20) and it may represent past and current exposure to such
neoepitopes. In certain instances, AHA can act as surrogate Fc and
restore effector function of proteolytically inactivated antibodies
(22). As one rationale for using a Fab or F(ab').sub.2 molecule as
the therapeutic format is to eliminate effector function, it would
be undesirable to have effector function reinstated by pre-existing
AHA and risk any potential safety concerns. Accordingly, there is a
need in the art for novel Fab and F(ab').sub.2 molecules that have
reduced or no reactivity with pre-existing AHA in human serum to,
inter alia, potentially provide a superior safety profile in a
therapeutic setting by minimizing immune responses following drug
treatment.
SUMMARY
[0006] The present disclosure relates to antibody fragments (e.g.,
Fab and F(ab').sub.2) having reduced or no reactivity towards
pre-existing anti-hinge antibodies (AHA) and compositions
comprising such antibody fragments, as well as methods of making
and using such antibody fragments and compositions.
[0007] In certain embodiments, the present disclosure is directed
to an isolated antibody fragment and compositions comprising the
same, wherein the antibody fragment has reduced or no reactivity
towards pre-existing anti-hinge antibodies. In certain embodiments,
an isolated antibody fragment of the present disclosure exhibits
reduced and/or no binding to FcyRIIIa and/or C1q. In certain
embodiments, the antibody fragment is a Fab, Fab' or
F(ab').sub.2.
[0008] In certain embodiments, the present disclosure is directed
to antibody fragments and compositions comprising the same, wherein
the antibody fragment is a Fab. In certain embodiments, the present
disclosure is directed to Fab molecules wherein the Fab terminates
with residue D.sub.221. In certain embodiments, the Fab terminates
with amino acids comprising an amino acid sequence selected from
group consisting of CDKTHT (SEQ ID NO: 14), CDKTHL (SEQ ID NO: 15),
CDKTH (SEQ ID NO: 16), CDKT (SEQ ID NO: 17), CDK and CD. In certain
embodiments, the Fab terminates with amino acids comprising an
amino acid sequence selected from group consisting of KYGPP (SEQ ID
NO: 18), KYGP (SEQ ID NO: 19), KYG, KY and K. In certain
embodiments, the Fab comprises a heavy chain constant region that
comprises an amino acid sequence selected from the group consisting
of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and
conservative modifications of.
[0009] In certain embodiments, the present disclosure is directed
to an antibody fragment and compositions comprising the same,
wherein the antibody fragment is a F(ab').sub.2. In certain
embodiments, the present disclosure is directed to F(ab').sub.2
molecules, wherein the F(ab').sub.2 comprises a C-terminal deletion
of 1, 2, 3, 4, or 5 amino acids. In certain embodiments of the
present disclosure, the F(ab').sub.2 comprises a deletion at
position EU231. In certain embodiments of the present disclosure,
the F(ab').sub.2 comprises a deletion at positions EU231-232. In
certain embodiments of the present disclosure, the F(ab').sub.2
comprises a deletion at positions EU231-233. In certain embodiments
of the present disclosure, the F(ab').sub.2 comprises a deletion at
position EU231-234. In certain embodiments, the F(ab').sub.2
comprises a deletion at position EU230-234.
[0010] In certain embodiments, the present disclosure is directed
to an isolated nucleic acid and compositions comprising the same,
wherein the nucleic acid encodes an antibody fragment having
reduced or no reactivity to AHA. In certain embodiments, the
present disclosure is directed to a host cell comprising said
nucleic acid. In certain embodiments, the present disclosure is
directed to a method of producing an antibody fragment comprising
culturing said host cell so that the antibody fragment is produced.
In certain embodiments, the present disclosure is directed to a
pharmaceutical formulation comprising an antibody fragment having
reduced or no reactivity to AHA and a pharmaceutically acceptable
carrier.
[0011] In certain embodiments, the present disclosure is directed
to an antibody fragment having reduced or no reactivity to AHA for
use as a medicament. In certain embodiments, the present disclosure
is directed to an antibody fragment having reduced or no reactivity
to AHA for use in treating a disease. In certain embodiments, the
present disclosure is directed to an antibody fragment having
reduced or no reactivity to AHA for use in inhibiting or activating
a molecular pathway and/or mechanism. In certain embodiments, the
present disclosure is directed to the use of an antibody fragment
having reduced or no reactivity to AHA in the manufacture of a
medicament for the treatment of a disease. In certain embodiments,
the present disclosure is directed to the use of an antibody
fragment having reduced or no reactivity to AHA in the manufacture
of a medicament for inhibiting or activating a molecular pathway
and/or mechanism.
[0012] In certain embodiments, the present disclosure is directed
to methods of treating an individual having a disease comprising
administering to the individual an effective amount of an antibody
fragment having reduced or no reactivity to AHA. In certain
embodiments, the present disclosure is directed to methods of
inhibiting or activating a molecular pathway and/or mechanism in an
individual comprising administering to the individual an effective
amount of an antibody fragment having reduced or no reactivity to
AHA to inhibit or activate a molecular pathway and/or mechanism
BRIEF DESCRIPTION OF THE FIGURES
[0013] FIGS. 1A-1D show the binding of pre-existing human
antibodies to the Fab of human IgG1, IgG2 and IgG4. (1A) X-ray
crystal structure of the Fab region (PDB: 1HZH) including the upper
hinge; light chain (101), heavy chain (102), interchain disulfide
(103), and upper hinge (104). In the isolated Fab molecule the
upper hinge is a protruding unstructured region without structural
and functional role. The residues of the upper hinge are displayed
in magenta to indicate the T225L mutation (105) that is perturbing
binding to pre-existing AHA. Numbering of residues is according to
EU numbering nomenclature. FIG. 1A discloses SEQ ID NOS 14-15,
respectively, in order of appearance. (1B) Pooled human serum was
incubated with human IgG1 Fab with different upper hinge lengths
and ends. Binding pre-existing antibodies detected by anti-Fc
ELISA. Truncating the Fab C-terminus to D.sub.221 (D) and the
C-terminal variant T225L (DKTHL (SEQ ID NO: 20)) greatly reduced
binding of pre-existing antibodies to almost background. Strong
response was observed towards T223 as the C-terminal residue (DKT),
coinciding with the cleavage site of human neutrophil elastase. The
mean value of the individual data points is represented by the
horizontal line. FIG. 1B discloses SEQ ID NOS 20-21 and 27,
respectively, in order of appearance. (1C) Three different Fabs
were incubated with pooled human serum and binding of pre-existing
antibodies detected by ELISA. Significant signal was observed for
different Fabs with DKTHT (SEQ ID NO: 21) C-terminus. Reduced
binding of pre-existing antibodies to the D.sub.221 and T.sub.225L
C-terminus was detected across different Fabs. Fab-1 includes the
antibody variable domain used in (B) and all other AHA binding
experiments throughout Example 1. FIG. 1C discloses SEQ ID NOS 21,
20, 21, 20, 21 and 20, respectively, in order of appearance. (1D)
Pooled human serum was incubated with human IgG2 Fab and IgG4 Fabs
with different upper hinge length and binding antibodies detected
by ELISA. No pre-existing antibodies can be detected to the upper
hinge of human IgG2 and IgG4. FIG. 1D discloses SEQ ID NO: 18.
[0014] FIGS. 2A-2C show the cleavage of IgG1-2 chimera by IdeS.
(2A) Model of the F(ab').sub.2 region of antibody cAC10 modeled
with MOE; light chain (201), heavy chain (202), interchain
disulfide (203), and lower hinge (204). The P1 position of IdeS is
G236. Numbering of residues is according to EU numbering
nomenclature. FIG. 2A discloses SEQ ID NO: 30. (2B) Alignment of
the lower hinge of IgG1 and the IgG1-2 chimera. Residues in cyan
are IgG2 isotype residues introduced into the lower hinge of IgG2.
FIG. 2B discloses SEQ ID NOS 31 and 59, respectively, in order of
appearance. (2C) Cleavage efficiency of human IgG1 and IgG1-2
chimera. 1 mg/ml of IgG1 and IgG1-2 were incubated for 24 hours at
37.degree. C. with different IdeS amounts as indicated. Cleavage
was analyzed by capillary electrophoresis. While IgG1 was
efficiently cleaved into F(ab').sub.2 at an IdeS:IgG ratio of
1:500, IgG1-2 requires 50-fold higher IdeS concentrations for
complete cleavage.
[0015] FIGS. 3A-3E show the cleavage of human IgG1 with variants in
the P1 and P2 position by IdeS. (3A) Capillary electrophoresis of
antibodies with variants at the P1 and P2 position were digested 24
hours at 37.degree. C. with a 1:10 ratio of IdeS:IgG at 1 mg/ml.
The P1 and P2 residues are designated in 1-letter code. Leucine and
glycine (L235G236) are the natural amino acids at these positions.
All antibody variants can be completely cleaved into F(ab').sub.2
fragments. (3B) The cleavage efficiency of the variants was
assessed by amount of F(ab').sub.2 produced at different IdeS:IgG
ratios. While the variant VG is cleaved comparably to the wild-type
sequence (LG), other variants require increased amounts of IdeS for
complete digestion. (3C) The cleavage efficiency of the variants
was assessed by the amount of F(ab').sub.2 produced at an IdeS:IgG
ratio of 1:10.
[0016] (3D) Schematic diagrams of the expression, purification and
screening strategies for the human IgG1 variants. FIG. 3D discloses
SEQ ID NOS 31-34, respectively, in order of appearance. (3E)
Cleavage efficiency of the 76 human IgG1 variants with IdeS. FIG.
3E discloses SEQ ID NO: 31.
[0017] FIGS. 4A-4B show the reactivity of P1 and P2 variants
towards pre-existing AHA. (4A) IdeS is efficiently removed during
purification and cannot be detected in the purified F(ab').sub.2
variants by SDS-PAGE followed by coomassie staining (upper panel)
or immunoblot analysis with anti-IdeS antibodies (lower panel).
(4B) Pooled human serum was incubated with human IgG1 Fab with T225
C-terminus and F(ab').sub.2 generated by IdeS cleavage of
antibodies with variants in P1 and P2 positions. Binding
pre-existing antibodies were detected by ELISA. The F(ab').sub.2
showed a signal that was about 1.7 fold higher compared to the Fab.
The hinge variants reduced reactivity to levels comparable to Fab
but did not eliminate reactivity completely.
[0018] FIGS. 5A-5F show the reactivity of truncated variants
towards pre-existing AHA response. (5A) IdeS cleavage of antibodies
with deletions in the IdeS P3, P4, and P5 sites. While deletion of
the IdeS P3 residue (L234) in the lower hinge severely impacted
cleavage efficiency, deletion of the P4 (E233) or P5 (P232)
positions did not impact cleavage with IdeS compared to wild-type
(WT). (5B) Deletion of the P4 and P5 positions was not sufficient
to avoid binding of pre-existing AHA. (5C) IdeS cleavage of
antibodies with deletions of the IdeS P4 through P6 (AP456) and P4
through P7 (.DELTA.P4567) sites. While cleavage efficiency of the
.DELTA.P4567 variant was slightly reduced compared to the wild-type
lower hinge sequence (WT), .DELTA.P456 displayed cleavage
efficiency comparable to the wild-type at IdeS:IgG ratio of 1:200.
(5D) Pooled human serum was incubated with F(ab').sub.2 produced by
IdeS digestion and binding antibodies detected by ELISA. Lower
hinge deletions .DELTA.P456 and .DELTA.P4567 were not recognized by
pre-existing AHA. (5E) IdeS cleaved the .DELTA.P456 hinge variant
with high specificity. After digestion of wild-type (WT) and
.DELTA.P456 hinge IgG, reduced F(ab').sub.2 was analyzed by mass
spectrometry. Only a single heavy chain species corresponding to
the expected molecular mass was observed. (5F) Schematic diagram
depicting the deletions generated in the lower hinge region. FIG.
5F discloses SEQ ID NOS 35, 31, 36-40, 31, and 41-42, respectively,
in order of appearance.
[0019] FIGS. 6A-6B show the alignment of the amino acid residues
(6A) and EU numbering of the amino acid residues (6B) within the
upper, core and lower hinge regions of the IgG1, IgG2, IgG3 and
IgG4 isotypes in human, cynomolgus monkey and rhesus monkey. FIG.
6A discloses SEQ ID NOS 43-54, respectively, in order of
appearance. FIG. 6B discloses SEQ ID NOS 43, 46, 55 and 52,
respectively, in order of appearance.
[0020] FIG. 7 shows the expression levels of Fabs with upper hinge
truncations or mutations in E. coli. Figure discloses SEQ ID NOS
14-15, respectively, in order of appearance.
[0021] FIG. 8 shows the efficiency of the cleavage of the
.DELTA.P456 and .DELTA.P4567 variant produced at an IdeS:IgG ratio
of 1:500 or 1:10. Figure discloses SEQ ID NOS 56-58, respectively,
in order of appearance.
[0022] FIGS. 9A-9D show the reactivity of deletion variants with
modified P1 and P2 residues with pre-existing AHA. (9A) The
cleavage efficiency of the variants was assessed by amount of
F(ab').sub.2 produced at an IdeS:IgG ratio of 1:10. FIG. 9A
discloses SEQ ID NO: 31. (9B) The cleavage efficiency of the
variants was assessed by the amount of F(ab').sub.2 produced at an
IdeS:IgG ratio of 1:100. FIG. 9B discloses SEQ ID NO: 31. (9C) The
cleavage efficiency of the variants was assessed by amount of
F(ab').sub.2 produced at an IdeS:IgG ratio of 1:500. FIG. 9C
discloses SEQ ID NO: 31. (9D) Detection of the bound pre-existing
AHA to the variants by anti-Fc ELISA. FIG. 9D discloses SEQ ID NO:
56.
[0023] FIGS. 10A-10B show the reactivity of the .DELTA.P456 and
.DELTA.P4567 variants with modified P1 and P2 residues to
pre-existing AHA. (10A) The cleavage efficiency of the variants was
assessed by amount of F(ab').sub.2 produced at an IdeS:IgG ratio of
1:10 and 1:200. FIG. 10A discloses SEQ ID NOS 56-57, respectively,
in order of appearance. (10B) Detection of pre-existing AHA bound
to the variants by anti-Fc ELISA. FIG. 10B discloses SEQ ID NO:
56.
[0024] FIG. 11 shows the titration curves of F(ab').sub.2 and Fab
molecules in the AHA ELISA. The dilutions corresponding to the OD
450 nm (1.15) at the middle of the F(ab').sub.2 titration curves
were 70 and 14 for F(ab').sub.2 and Fab, respectively. Thus,
F(ab').sub.2 has five fold higher AHA reactivity than IgG1 Fab.
F(ab').sub.2, F(ab').sub.2 .DELTA.P456, Fab T.sub.225, Fab
T.sub.225L and Fab D.sub.221 were coated on the wells. Serial
dilutions of pooled human serum were added to the wells and control
wells were uncoated. Similar results were obtained in 4 other
experiments. The data shown here and in FIG. 1B and FIG. 5D were
collected from the same experiment. Figure discloses SEQ ID NOS 21
and 20, respectively, in order of appearance.
DETAILED DESCRIPTION
I. DEFINITIONS
[0025] The term "antibody" herein is used in the broadest sense and
encompasses various antibody structures, including but not limited
to monoclonal antibodies, polyclonal antibodies, multispecific
antibodies (e.g., bispecific antibodies), and antibody fragments so
long as they exhibit the desired antigen-binding activity.
[0026] An "antibody fragment" refers to a molecule other than an
intact antibody that comprises a portion of an intact antibody that
binds the antigen to which the intact antibody binds. Examples of
antibody fragments include but are not limited to Fv, Fab, Fab',
Fab'-SH, F(ab').sub.2; diabodies; linear antibodies; single-chain
antibody molecules (e.g., scFv); and multispecific antibodies
formed from antibody fragments. In certain embodiments, the
antibody fragment is a Fab molecule. In certain embodiments, the
antibody fragment is a F(ab').sub.2 molecule.
[0027] The terms "full length antibody," "intact antibody," and
"whole antibody" are used herein interchangeably to refer to an
antibody having a structure substantially similar to a native
antibody structure or having heavy chains that contain an Fc region
as defined herein.
[0028] "Native antibodies" refer to naturally occurring
immunoglobulin molecules with varying structures. For example,
native IgG antibodies are heterotetrameric glycoproteins of about
150,000 daltons, composed of two identical light chains and two
identical heavy chains that are disulfide-bonded. From N- to
C-terminus, each heavy chain has a variable region (VH), also
called a variable heavy domain or a heavy chain variable domain,
followed by three constant domains (C.sub.H1, C.sub.H2, and
C.sub.H3). Similarly, from N- to C-terminus, each light chain has a
variable region (VL), also called a variable light domain or a
light chain variable domain, followed by a constant light (CL)
domain. The light chain of an antibody can be assigned to one of
two types, called kappa (.kappa.) and lambda (k), based on the
amino acid sequence of its constant domain.
[0029] The term "Fc region" herein is used to define a C-terminal
region of an immunoglobulin heavy chain that contains at least a
portion of the constant region. The term includes native sequence
Fc regions and variant Fc regions. Unless otherwise specified
herein, numbering of amino acid residues in the Fc region or
constant region is according to the EU numbering system, also
called the EU index, as described in Kabat et al., Sequences of
Proteins of Immunological Interest, 5th Ed. Public Health Service,
National Institutes of Health, Bethesda, Md., 1991.
[0030] "Fc receptor" or "FcR" describes a receptor that binds to
the Fc region of an antibody. Fc.gamma.RII receptors include
Fc.gamma.RIIA (an "activating receptor") and Fc.gamma.RIM (an
"inhibiting receptor"), which have similar amino acid sequences
that differ primarily in the cytoplasmic domains thereof.
Activating receptor Fc.gamma.RIIA contains an immunoreceptor
tyrosine-based activation motif (ITAM) in its cytoplasmic domain.
Inhibiting receptor Fc.gamma.RIM contains an immunoreceptor
tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain.
(see, e.g., Daeron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs
are reviewed, for example, in Ravetch and Kinet, Annu. Rev. Immunol
9:457-92 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de
Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs,
including those to be identified in the future, are encompassed by
the term "FcR" herein.
[0031] The term "Fc receptor" or "FcR" also includes the neonatal
receptor, FcRn, which is responsible for the transfer of maternal
IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim
et al., J. Immunol. 24:249 (1994)) and regulation of homeostasis of
immunoglobulins. Methods of measuring binding to FcRn are known
(see, e.g., Ghetie and Ward., Immunol. Today 18(12):592-598 (1997);
Ghetie et al., Nature Biotechnology, 15(7):637-640 (1997); Hinton
et al., J. Biol. Chem. 279(8):6213-6216 (2004); WO 2004/92219
(Hinton et al.).
[0032] Binding to human FcRn in vivo and serum half-life of human
FcRn high affinity binding polypeptides can be assayed, e.g., in
transgenic mice or transfected human cell lines expressing human
FcRn, or in primates to which the polypeptides with a variant Fc
region are administered. WO 2000/042072 (Presta) describes antibody
variants with improved or diminished binding to FcRs. See also,
e.g., Shields et al. J. Biol. Chem. 9(2):6591-6604 (2001).
[0033] "Effector functions" refer to those biological activities
attributable to the Fc region of an antibody, which vary with the
antibody isotype. Examples of antibody effector functions include:
C1q binding and complement dependent cytotoxicity (CDC); Fc
receptor binding; antibody-dependent cell-mediated cytotoxicity
(ADCC); phagocytosis; down regulation of cell surface receptors
(e.g. B cell receptor); and B cell activation.
[0034] The "hinge region" is generally defined as stretching from
216-238 (EU numbering) or 226-251 (Kabat numbering) of human IgG1.
The hinge can be further divided into three distinct regions, the
upper, middle (e.g., core) and lower hinge. See, e.g., Brerski and
Georgiou, Curr. Opin. Immunol. 40, 62-69 (2016), which is
incorporated by reference herein in its entirety. In certain
embodiments, the hinge region of a human IgG1 antibody is generally
defined as follows:
[0035] The upper hinge comprises amino acids having the sequence
EPKSCDKTHT (SEQ ID NO: 22). In certain embodiments, the upper hinge
comprises the amino acids at positions 216-225 (EU numbering) or
226-238 (Kabat numbering).
[0036] The middle (e.g., core) hinge comprises amino acids having
the sequence CPPC (SEQ ID NO: 23). In certain embodiments, the core
hinge comprises the amino acids at positions 226-229 (EU numbering)
or 239-242 (Kabat numbering).
[0037] The lower hinge comprises amino acids having the sequence
PAPELLGGP (SEQ ID NO: 24). In certain embodiments, the lower hinge
comprises the amino acids at positions 230-238 (EU numbering) or
243-251 (Kabat numbering).
[0038] The "class" of an antibody refers to the type of constant
domain or constant region possessed by its heavy chain. There are
five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and
several of these can be further divided into subclasses (isotypes),
e.g., IgG.sub.1, IgG.sub.2, IgG.sub.3, IgG.sub.4, IgA.sub.1, and
IgA.sub.2. The heavy chain constant domains that correspond to the
different classes of immunoglobulins are called .alpha., .delta., ,
.gamma. and .mu., respectively.
[0039] An "isolated" antibody or antibody fragment is one which has
been separated from a component of its natural environment. An
antibody or an antibody fragment can be purified to greater than
95% or 99% purity as determined by, for example, electrophoretic
(e.g., SDS-PAGE, isoelectric focusing (IEF), capillary
electrophoresis) or chromatographic (e.g., ion exchange or reverse
phase HPLC). For review of methods for assessment of antibody
purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87
(2007).
[0040] "Percent (%) amino acid sequence identity" with respect to a
reference polypeptide sequence is defined as the percentage of
amino acid residues in a candidate sequence that are identical with
the amino acid residues in the reference polypeptide sequence,
after aligning the sequences and introducing gaps, if necessary, to
achieve the maximum percent sequence identity, and not considering
any conservative substitutions as part of the sequence identity.
Alignment for purposes of determining percent amino acid sequence
identity can be achieved in various ways that are within the skill
in the art, for instance, using publicly available computer
software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR)
software. Those skilled in the art can determine appropriate
parameters for aligning sequences, including any algorithms needed
to achieve maximal alignment over the full length of the sequences
being compared. For purposes herein, however, % amino acid sequence
identity values are generated using the sequence comparison
computer program ALIGN-2. The ALIGN-2 sequence comparison computer
program was authored by Genentech, Inc., and the source code has
been filed with user documentation in the U.S. Copyright Office,
Washington D.C., 20559, where it is registered under U.S. Copyright
Registration No. TXU510087. The ALIGN-2 program is publicly
available from Genentech, Inc., South San Francisco, California, or
can be compiled from the source code. The ALIGN-2 program should be
compiled for use on a UNIX operating system, including digital UNIX
V4.0D. All sequence comparison parameters are set by the ALIGN-2
program and do not vary.
[0041] In situations where ALIGN-2 is employed for amino acid
sequence comparisons, the % amino acid sequence identity of a given
amino acid sequence A to, with, or against a given amino acid
sequence B (which can alternatively be phrased as a given amino
acid sequence A that has or comprises a certain % amino acid
sequence identity to, with, or against a given amino acid sequence
B) is calculated as follows:
100 times the fraction X/Y
where X is the number of amino acid residues scored as identical
matches by the sequence alignment program ALIGN-2 in that program's
alignment of A and B, and where Y is the total number of amino acid
residues in B. It will be appreciated that where the length of
amino acid sequence A is not equal to the length of amino acid
sequence B, the % amino acid sequence identity of A to B will not
equal the % amino acid sequence identity of B to A. Unless
specifically stated otherwise, all % amino acid sequence identity
values used herein are obtained as described in the immediately
preceding paragraph using the ALIGN-2 computer program.
[0042] An "isolated" nucleic acid refers to a nucleic acid molecule
that has been separated from a component of its natural
environment. An isolated nucleic acid includes a nucleic acid
molecule contained in cells that ordinarily contain the nucleic
acid molecule, but the nucleic acid molecule is present
extrachromosomally or at a chromosomal location that is different
from its natural chromosomal location.
[0043] The term "vector," as used herein, refers to a nucleic acid
molecule capable of propagating another nucleic acid to which it is
linked. The term includes the vector as a self-replicating nucleic
acid structure as well as the vector incorporated into the genome
of a host cell into which it has been introduced. Certain vectors
are capable of directing the expression of nucleic acids to which
they are operatively linked. Such vectors are referred to herein as
"expression vectors."
[0044] The terms "host cell," "host cell line," and "host cell
culture" are used interchangeably and refer to cells into which
exogenous nucleic acid has been introduced, including the progeny
of such cells. Host cells include "transformants" and "transformed
cells," which include the primary transformed cell and progeny
derived therefrom without regard to the number of passages. Progeny
can be completely identical in nucleic acid content to a parent
cell, or can contain mutations. Mutant progeny that have the same
function or biological activity as screened or selected for in the
originally transformed cell are included herein.
[0045] An "individual" or "subject" is a mammal. Mammals include,
but are not limited to, domesticated animals (e.g., cows, sheep,
cats, dogs, and horses), primates (e.g., humans and non-human
primates such as monkeys), rabbits, and rodents (e.g., mice and
rats). In certain embodiments, the individual or subject is a
human.
[0046] As used herein, "treatment" (and grammatical variations
thereof such as "treat" or "treating") refers to clinical
intervention in an attempt to alter the natural course of the
individual being treated, and can be performed either for
prophylaxis or during the course of clinical pathology. Desirable
effects of treatment include, but are not limited to, preventing
occurrence or recurrence of disease, alleviation of symptoms,
diminishment of any direct or indirect pathological consequences of
the disease, preventing metastasis, decreasing the rate of disease
progression, amelioration or palliation of the disease state, and
remission or improved prognosis. In certain embodiments, antibody
fragments of the present disclosure are used to delay development
of a disease or to slow the progression of a disease.
[0047] An "effective amount" of an agent, e.g., an antibody
fragment disclosed herein, or a pharmaceutical formulation
comprising an agent, refers to an amount effective, at dosages and
for periods of time necessary, to achieve the desired therapeutic
or prophylactic result.
[0048] The term "package insert" is used to refer to instructions
customarily included in commercial packages of therapeutic
products, that contain information about the indications, usage,
dosage, administration, combination therapy, contraindications
and/or warnings concerning the use of such therapeutic
products.
[0049] The term "pharmaceutical formulation" refers to a
preparation which is in such form as to permit the biological
activity of an active ingredient contained therein to be effective,
and which contains no additional components which are unacceptably
toxic to a subject to which the formulation would be
administered.
[0050] A "pharmaceutically acceptable carrier" refers to an
ingredient in a pharmaceutical formulation, other than an active
ingredient, which is nontoxic to a subject. A pharmaceutically
acceptable carrier includes, but is not limited to, a buffer,
excipient, stabilizer, or preservative.
[0051] The term "cytotoxic agent" as used herein refers to a
substance that inhibits or prevents a cellular function and/or
causes cell death or destruction. Cytotoxic agents include, but are
not limited to, radioactive isotopes (e.g., At.sup.211, I.sup.131,
I.sup.125, Y.sup.90, Re.sup.186, Re.sup.188, Sm.sup.153,
Bi.sup.212, P.sup.32, Pb.sup.212 and radioactive isotopes of Lu);
chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin,
vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin,
melphalan, mitomycin C, chlorambucil, daunorubicin or other
intercalating agents); growth inhibitory agents; enzymes and
fragments thereof such as nucleolytic enzymes; antibiotics; toxins
such as small molecule toxins or enzymatically active toxins of
bacterial, fungal, plant or animal origin, including fragments
and/or variants thereof; and the various antitumor or anticancer
agents disclosed below.
[0052] As used herein, the term "about" or "approximately" means
within an acceptable error range for the particular value as
determined by one of ordinary skill in the art, which will depend
in part on how the value is measured or determined, i.e., the
limitations of the measurement system. For example, "about" can
mean within 3 or more than 3 standard deviations, per the practice
in the art. Alternatively, "about" can mean a range of up to 20%,
preferably up to 10%, more preferably up to 5%, and more preferably
still up to 1% of a given value. Alternatively, particularly with
respect to biological systems or processes, the term can mean
within an order of magnitude, preferably within 5-fold, and more
preferably within 2-fold, of a value.
II. COMPOSITIONS AND METHODS
[0053] In certain embodiments, the present disclosure is based, in
part, on methods of engineering antibody fragments to evade
pre-existing anti-hinge antibodies (AHA). In certain embodiments,
antibody fragments (e.g., Fab and F(ab').sub.2) that have reduced
or no reactivity towards AHA and methods of making these antibody
fragments are provided. In certain embodiments, antibody fragments
of the present disclosure can provide superior safety in a
therapeutic setting by minimizing immune response following drug
treatments.
A. Exemplary Antibody Fragments
[0054] In certain embodiments, the present disclosure provides
antibody fragments (e.g., Fab, Fab' and F(ab').sub.2), and
compositions comprising the same, that have reduced or no
reactivity towards AHA. For example, but not by way of limitation,
an antibody fragment disclosed herein exhibits AHA reactivity that
is reduced by at least 10%, at least 20%, at least 30%, at least
40%, at least 50%, at least 60%, at least 70%, at least 80%, at
least 90% or at least 100% relative to a reference antibody
fragment, e.g., an antibody fragment with a native hinge region. In
certain embodiments, the reference antibody fragment is an IgG1
antibody fragment that has a native hinge region.
[0055] In certain embodiments, the isolated antibody fragments of
the present disclosure, and the compositions comprising the same,
exhibit reduced and/or no binding to Fc.gamma.RIIIa and/or C1q. For
example, and not by way of limitation, an antibody fragment of the
present disclosure exhibits binding to Fc.gamma.RIIIa and/or C1q
that is reduced by at least 10%, at least 20%, at least 30%, at
least 40%, at least 50%, at least 60%, at least 70%, at least 80%,
at least 90% or at least 100% relative to a reference antibody
fragment, e.g., an antibody fragment with a native hinge region. In
certain embodiments, the reference antibody fragment is an IgG1
antibody fragment that has a native hinge region.
[0056] In certain embodiments, an antibody fragment employed in the
context of the methods described herein comprises a native hinge
region or a modified hinge region. For example, and not by way of
limitation, an antibody fragment of the present disclosure can be a
Fab fragment that comprises a native hinge region or modified hinge
region. In certain embodiments, the antibody fragment of the
present disclosure is a F(ab').sub.2 that comprises a native hinge
region or modified hinge region.
[0057] A native hinge region is a hinge region normally associated
with the C.sub.H1 domain of an antibody molecule. In certain
embodiments, the native hinge region of a presently disclosed
antibody fragment can be of the IgG1, IgG2, IgG3 or IgG4 isotype.
For example, and not by way of limitation, the Fab fragment can be
of the IgG1, IgG2, IgG3 or IgG4 isotype. In certain embodiments,
the antibody fragment, e.g., the Fab fragment, is of the IgG2
isotype comprising a native hinge region. In certain embodiments,
the antibody fragment, e.g., the Fab fragment, is of the IgG4
isotype comprising a native hinge region.
[0058] A modified hinge region is any hinge that differs in length
and/or composition from the native hinge region. Such hinges can
include hinge regions from other species, such as human, mouse,
rat, rabbit, pig, hamster, camel, llama or goat hinge regions.
Other modified hinge regions can comprise a complete hinge region
derived from an antibody of a different class or subclass from that
of the C.sub.H1 domain. Thus, for instance, a C.sub.H1 domain of
class .gamma.1 can be attached to a hinge region of class .gamma.4.
Alternatively, the modified hinge region can comprise part of a
natural hinge or a repeating unit in which each unit in the repeat
is derived from a natural hinge region.
[0059] In certain embodiments, the native hinge region is altered
by substituting, deleting and/or adding one or more amino acid
residues to generate a modified hinge region. In certain
embodiments, the Fab fragment is of the IgG1 isotype comprising a
modified hinge region. In certain embodiments, the Fab fragment is
of the IgG2 isotype comprising a modified hinge region. In certain
embodiments, the Fab fragment is of the IgG4 isotype comprising a
modified hinge region.
[0060] In certain embodiments, a modified hinge region comprises
the substitution, deletion and/or addition of one or more amino
acids within the upper hinge region. For example, and not by way of
limitation, a modified hinge region of the disclosed subject matter
can have one or more substitutions, deletions and/or additions at
amino acid positions EU216-225. Alternatively or additionally, a
modified hinge region comprises the substitution, deletion and/or
addition of one or more amino acids within the lower hinge region.
In certain embodiments, a modified hinge region of the disclosed
subject matter can have one or more substitutions, deletions and/or
additions at amino acid positions EU230-238. Alternatively or
additionally, a modified hinge region can comprise the addition of
one or more amino acids C-terminal to amino acid position EU238. In
certain embodiments, a modified hinge region comprises the
substitution, deletion and/or addition of one or more amino acids
within the middle, e.g., core, hinge region. For example, and not
by way of limitation, a modified hinge region of the disclosed
subject matter can have one or more substitutions, deletions and/or
additions at amino acid positions EU226-229.
[0061] In certain embodiments, the modification or alteration is a
substitution of one or more, two or more, three or more, four or
more, five or more or six or more amino acid residues. In certain
embodiments, the substitution can be generated within the upper
hinge region, middle hinge region and/or the lower hinge region. In
certain embodiments, the amino acid residue at position 225 can be
substituted. For example, and not by way of limitation, the amino
acid residue at position 225 can be changed to any amino acid
except for threonine (T). In certain embodiments, the amino acid at
position 225, e.g., threonine, can be changed to a leucine (L),
e.g., T225L, according to EU numbering. In certain embodiments, an
antibody fragment of the present disclosure is a Fab fragment
comprising the substitution T225L.
[0062] In certain embodiments, the upper hinge region of an IgG1
antibody fragment can be substituted with one or more amino acids
residues present within the upper hinge region of an IgG2 and/or an
IgG4 antibody because, for example, the upper hinge regions of IgG2
and IgG4 antibodies exhibit reduced or no reactivity towards AHA
(see, e.g., FIG. 1). For example, and not by way of limitation, the
upper hinge region of an IgG1 antibody fragment can be substituted
with one or more amino acids residues present within the native
hinge region of an IgG2 and/or an IgG4 antibody (see FIG. 6). In
certain embodiments, a modified hinge region of an IgG1 antibody
fragment retains a cysteine at amino acid position EU220 (e.g., as
compared to the native hinge region of an IgG1 antibody). In
certain embodiments, a modified hinge region of an IgG1 antibody
fragment does not retain a cysteine at amino acid position EU220,
e.g., in an IgG antibody fragment where the upper hinge region of
the IgG1 antibody fragment is replaced with the upper hinge region
(e.g., entire upper hinge region) of IgG4. In certain embodiments,
the upper hinge region of an IgG1 antibody fragment can be
substituted with one or more amino acids residues present within
the upper hinge region of an IgG2, IgG3 and/or an IgG4 antibody,
where the amino acid residue at position 131 of the IgG1 antibody
is changed from a serine (S) to a cysteine (C), i.e., S131C.
[0063] In certain embodiments, an antibody fragment of the present
disclosure, e.g., a Fab, F(ab').sub.2 or Fab', can comprise a
substitution at amino acid positions EU235-236. For example, and
not by way of limitation, the amino acid at position 236, e.g.,
glycine (G), can be changed to an alanine (A), e.g., G236A. In
certain embodiments, an antibody fragment, e.g., a F(ab').sub.2,
can comprise a substitution at position 235, according to EU
numbering. In certain embodiments, the amino acid at position 235,
e.g., leucine (L), can be changed to a valine (V), e.g., L235V,
changed to an isoleucine (I) e.g., L235I, or changed to a
methionine (M) e.g., L235M.
[0064] In certain embodiments, the modification or alteration is a
deletion of one or more, two or more, three or more, four or more,
five or more or six or more amino acid residues. In certain
embodiments, the one or more deletions can be generated within the
upper hinge region, middle hinge region and/or the lower hinge
region. In certain embodiments, an antibody fragment of the present
disclosure, e.g., a Fab, F(ab').sub.2 or Fab', comprises a modified
hinge region that has one or more deletions of one or more amino
acids at positions EU230-238. In certain embodiments, the antibody
fragment comprises a deletion at position EU231. In certain
embodiments, the antibody fragment comprises a deletion at
positions EU231 and EU232. In certain embodiments, the antibody
fragment comprises deletions at positions EU231, EU232 and EU233.
In certain embodiments, the antibody fragment comprises deletions
at positions EU231, EU232, EU233 and EU234. In certain embodiments,
the antibody fragment comprises deletions at positions EU230,
EU231, EU232, EU233 and EU234.
[0065] In certain embodiments, an antibody fragment of the present
disclosure comprises a C-terminal deletion of one or more, two or
more, three or more, four or more, five or more or six or more
amino acids. In certain embodiments, an antibody fragment of the
present comprises the deletion of one or more amino acids in the
upper hinge region, e.g., to generate a C-terminal truncation. In
certain embodiments, one or more amino acid at positions EU222-225
can be deleted to obtain a C-terminal truncation. In certain
embodiments, an antibody fragment disclosed herein, e.g., a Fab
fragment, comprises a C-terminal truncation. For example, and not
by way of limitation, the C-terminus of an antibody fragment
disclosed herein, e.g., a Fab fragment, terminates at amino acid
residue D.sub.221 (according to EU numbering). In certain
embodiments, the C-terminus of an antibody fragment disclosed
herein, e.g., a Fab fragment, terminates at amino acid residue K222
(according to EU numbering).
[0066] In certain embodiments, the C-terminus of the heavy chain of
an antibody fragment, e.g., a Fab fragment, disclosed herein,
terminates with amino acids having a sequence selected from CDKTHT
(SEQ ID NO: 14), CDKTHL (SEQ ID NO: 15), CDKTH (SEQ ID NO: 16),
CDKT (SEQ ID NO: 17), CDK and CD. In certain embodiments, the
C-terminus of the heavy chain of the Fab fragment terminates in the
amino acid sequence CDKTHX (SEQ ID NO: 25), wherein X is any amino
acid except T. In certain embodiments, a Fab fragment comprises a
heavy chain constant region selected from "CDKTHT," (SEQ ID NO: 14)
"CDKTHL," (SEQ ID NO: 15) "CDKTH," (SEQ ID NO: 16) "CDKT," (SEQ ID
NO: 17) "CDK" or "CD," as disclosed in Table 1. In certain
embodiments, the presently disclosed subject matter provides
antibody fragments, e.g., Fab fragment, that comprise a heavy chain
constant region that comprises an amino acid sequence as set forth
in SEQ ID NOs: 1, 2, 3, 4, 5 or 6. In certain embodiments, an
antibody fragment of the present disclosure comprises a heavy chain
constant region that comprises the amino acid sequence set forth in
SEQ ID NO:5. In certain embodiments, an antibody fragment of the
present disclosure comprises a heavy chain constant region that
comprises the amino acid sequence set forth in SEQ ID NO:6.
[0067] In certain embodiments, as an alternative to truncation
and/or mutation at the C-terminus, to avoid pre-existing AHA
responses, IgG2 or IgG4 Fab fragments can be used. For example, and
not by way of limitation, an antibody fragment of the present
disclosure can comprise a heavy chain constant region that
comprises the amino acid sequence in SEQ ID NOs: 7 or 8. In certain
embodiments, an IgG2 or IgG4 Fab fragment can comprise a C-terminal
deletion of one or more, two or more, three or more, four or more
or five or more amino acids. In certain embodiments, a Fab of the
present disclosure is an IgG2 Fab fragment comprising a heavy chain
constant region ending in the sequence VERK (SEQ ID NO: 26). In
certain embodiments, the C-terminus of the heavy chain of an
antibody fragment, e.g., an IgG4 Fab fragment, disclosed herein,
terminates with amino acids having a sequence selected from KYGPP
(SEQ ID NO: 18), KYGP (SEQ ID NO: 19), KYG, KY and K. In certain
embodiments, a Fab of the present disclosure is an IgG4 Fab
fragment comprising a heavy chain constant region selected from
"KYGPP," (SEQ ID NO: 18) "KYGP," (SEQ ID NO: 19) "KYG," "KY" and
"K," as disclosed in Table 1. For example, and not by way of
limitation, an antibody fragment of the present disclosure can
comprise a heavy chain constant region that comprises the amino
acid sequence set forth in SEQ ID NOs: 9, 10, 11, 12 or 13.
TABLE-US-00001 TABLE 1 Fab Heavy Chain Sequences Fab heavy chain
ASTKG PSVFPLAPSS KSTSGGTAAL constant region GCLVKDYFPE PVTVSWNSGA
LTSGVHTFPA "CDKTHT" (SEQ ID VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NO:
14) NHKPSNTKVD KKVEPKSCDK THT (SEQ ID NO: 1) Fab heavy chain ASTKG
PSVFPLAPSS KSTSGGTAAL constant region GCLVKDYFPE PVTVSWNSGA
LTSGVHTFPA "CDKTHL" (SEQ ID VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NO:
15) NHKPSNTKVD KKVEPKSCDK THL (SEQ ID NO: 2) Fab heavy chain ASTKG
PSVFPLAPSS KSTSGGTAAL constant region GCLVKDYFPE PVTVSWNSGA
LTSGVHTFPA "CDKTH" (SEQ ID VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NO: 16)
NHKPSNTKVD KKVEPKSCDK TH (SEQ ID NO: 3) Fab heavy chain ASTKG
PSVFPLAPSS KSTSGGTAAL constant region GCLVKDYFPE PVTVSWNSGA
LTSGVHTFPA "CDKT" (SEQ ID VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NO: 17)
NHKPSNTKVD KKVEPKSCDK T (SEQ ID NO: 4) Fab heavy chain ASTKG
PSVFPLAPSS KSTSGGTAAL constant region GCLVKDYFPE PVTVSWNSGA
LTSGVHTFPA "CDK") VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD
KKVEPKSCDK (SEQ ID NO: 5) Fab heavy chain ASTKG PSVFPLAPSS
KSTSGGTAAL constant region GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA "CD"
VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KKVEPKSCD (SEQ ID NO:
6) Fab heavy chain ASTKG PSVFPLAPCS RSTSESTAAL constant region
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA IgG2 VLQSSGLYSL SSVVTVPSSN
FGTQTYTCNV DHKPSNTKVD KTVERK (SEQ ID NO: 7) Fab heavy chain ASTKG
PSVFPLAPCS RSTSESTAAL constant region GCLVKDYFPE PVTVSWNSGA
LTSGVHTFPA IgG4 VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV DHKPSNTKVD
KRVESKYGPP (SEQ ID NO: 8) Fab heavy chain ASTKG PSVFPLAPCS
RSTSESTAAL constant region GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA IgG4
("KYG") VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV DHKPSNTKVD KRVESKYG (SEQ
ID NO: 9) Fab heavy chain ASTKG PSVFPLAPCS RSTSESTAAL constant
region GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA IgG4 ("KYGP") VLQSSGLYSL
SSVVTVPSSS LGTKTYTCNV (SEQ ID NO: 19) DHKPSNTKVD KRVESKYGP (SEQ ID
NO: 10) Fab heavy chain ASTKG PSVFPLAPCS RSTSESTAAL constant region
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA IgG4 ("KYGPP") VLQSSGLYSL
SSVVTVPSSS LGTKTYTCNV (SEQ ID NO: 18) DHKPSNTKVD KRVESKYGPP (SEQ ID
NO: 11) Fab heavy chain ASTKG PSVFPLAPCS RSTSESTAAL constant region
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA IgG4 ("KY") VLQSSGLYSL SSVVTVPSSS
LGTKTYTCNV DHKPSNTKVD KRVESKY (SEQ ID NO: 12) Fab heavy chain ASTKG
PSVFPLAPCS RSTSESTAAL constant region GCLVKDYFPE PVTVSWNSGA
LTSGVHTFPA IgG4 ("K") VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV DHKPSNTKVD
KRVESK (SEQ ID NO: 13)
[0068] The present disclosure further provides antibody fragments
that comprise conservative modifications of the sequences disclosed
herein. For example, and not by way of limitation, the present
disclosure provides antibody fragments that comprise a heavy chain
constant region that comprises an amino acid sequence set forth in
SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or
conservative modifications thereof, and wherein the antibody
fragment retains the desired properties of the antibody fragments
disclosed herein. For example, and not by way of limitation, such
antibody fragments have reduced or no reactivity towards AHA, as
disclosed above.
[0069] As used herein, the term "conservative sequence
modification" is intended to refer to amino acid modifications that
do not significantly affect characteristics of the antibody
fragment containing the amino acid sequence. Such conservative
modifications include amino acid substitutions, additions and
deletions. Modifications can be introduced into an antibody
fragment of the present disclosure by standard techniques known in
the art, such as site-directed mutagenesis and PCR-mediated
mutagenesis. Conservative amino acid substitutions are ones in
which the amino acid residue is replaced with an amino acid residue
having a similar side chain. Families of amino acid residues having
similar side chains have been defined in the art. Exemplary
conservative amino acid substitutions are shown in Table 2.
[0070] In certain embodiments, a sequence disclosed herein can have
up to about one, up to about two, up to about three, up to about
four, up to about five, up to about six, up to about seven, up to
about eight, up to about nine or up to about ten amino acid
residues that are modified and/or substituted.
[0071] Amino acids can be grouped according to common side-chain
properties: [0072] i. hydrophobic: Norleucine, Met, Ala, Val, Leu,
Ile; [0073] ii. neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
[0074] iii. acidic: Asp, Glu; [0075] iv. basic: His, Lys, Arg;
[0076] v. residues that influence chain orientation: Gly, Pro;
[0077] vi. aromatic: Trp, Tyr, Phe. In certain embodiments,
non-conservative substitutions can entail exchanging a member of
one of these classes for another class.
TABLE-US-00002 [0077] TABLE 2 Original Residue Exemplary
Substitutions Preferred Substitutions Ala (A) Val; Leu; Ile Val Arg
(R) Lys; Gln; Asn Lys Asn (N) Gln; His; Asp, Lys; Arg Gln Asp (D)
Glu; Asn Glu Cys (C) Ser; Ala Ser Gln (Q) Asn; Glu Asn Glu (E) Asp;
Gln Asp Gly (G) Ala Ala His (H) Asn; Gln; Lys; Arg Arg Ile (I) Leu;
Val; Met; Ala; Phe; Leu Norleucine Leu (L) Norleucine; Ile; Val;
Met; Ile Ala; Phe Lys (K) Arg; Gln; Asn Arg Met (M) Leu; Phe; Ile
Leu Phe (F) Trp; Leu; Val; Ile; Ala; Tyr Tyr Pro (P) Ala Ala Ser
(S) Thr Thr Thr (T) Val; Ser Ser Trp (W) Tyr; Phe Tyr Tyr (Y) Trp;
Phe; Thr; Ser Phe Val (V) Ile; Leu; Met; Phe; Ala; Leu
Norleucine
[0078] Other modified hinge regions of the present disclosure can
be entirely synthetic and can be designed to possess desired
properties such as length, composition and flexibility. For
example, and not by way of limitation, a modified hinge region of
the present disclosure can be altered to increase or decrease the
flexibility of the hinge region. For example, and not by way of
limitation, modifications which can increase the flexibility of the
hinge region include, but are not limited to, the substitution of
one or more amino acids residues with one or more amino acid
residues which increase the flexibility (e.g., glycine). In certain
embodiments, modifications which can decrease the flexibility of
the hinge region include, but are not limited to, the substitution
of one or more amino acids residues with one or more amino acid
residues which crease the rigidity of the polypeptide (e.g.,
proline).
B. Methods of Making Antibody Fragments
[0079] In certain embodiments, the antibody fragments are made by
hinge engineering technology.
[0080] In certain embodiments, the antibody fragment starting
material for use in connection with the methods described herein
can be obtained from any whole antibody (e.g., a whole monoclonal
antibody), using any suitable enzymatic cleavage and/or digestion
techniques. In certain embodiments, the antibody fragment can be
obtained by cleavage with IdeS.
[0081] In certain embodiments, Fab molecules are generated by
proteolytic digestion or recombinant expression. Proteolytic
digestion was the original method of Fab production (6). Generating
Fab molecules via proteolytic digestion results in the C-terminal
sequence of the Fab heavy chain defined by the protease cleavage
site. In turn, a Fab molecule typically includes a portion of the
upper hinge of the antibody. This upper hinge region of the
antibody serves as the linker between Fab and Fc region but has no
structural or functional role in a Fab molecule. It can be
considered as an unstructured appendix (see FIG. 1A) as it is often
not fully resolved in crystal structures of Fab molecules. One
therapeutic Fab molecule directed against platelet surface receptor
GPITh/IIIa (abciximab, REOPRO.RTM.) is commercially produced by
proteolytic cleavage.
[0082] With the advances in molecular cloning, recombinant
expression of antibody fragments is an attractive route to generate
Fab molecules (7). In contrast to proteolytic digestion as a
production route, the recombinant expression of Fab molecules
provides flexibility in defining the length of the included upper
hinge region. In certain embodiments, the Fab fragments are
produced by recombinant expression.
[0083] The high affinity of an antibody is often enabled by
bivalent target engagement, facilitating avidity. In contrast, the
target engagement of a Fab is monovalent. This often leads to lower
target affinity compared to the full-length IgG. By joining two Fab
fragments to create a F(ab').sub.2, avidity can be restored while
preserving key properties of the Fab, such as short serum
half-life. In addition, targeting multiple disease mediators by
bispecific antibodies has become increasingly important for
therapeutic antibody development (8). F(ab').sub.2 molecules can
provide a natural scaffold to produce small bispecific antibody
fragments. In contrast to the production of Fab molecules, the
recombinant expression of F(ab').sub.2 is not naturally possible
because expressed Fab' molecules require non-native homo- or
heterodimerization domains as a fusion (9, 10). Hence, there are
two main approaches to generate F(ab').sub.2 molecules: (i)
chemical conjugation and (ii) proteolytic digestion. For chemical
conjugation, recombinantly generated Fab' molecules are coupled by
homo- or heterobifunctional crosslinkers (3, 9, 11, 12). Analogous
to the proteolytic digestion approach to produce Fab molecules, a
number of known proteases can cleave the intact antibody in the
lower hinge region to produce F(ab').sub.2 molecules (13). Such
proteolytic digestion results in very stable F(ab').sub.2 molecules
where the two Fab molecules are connected by the two
disulfide-bonds of the core-hinge. Pepsin is most widely used (14)
but a highly specific IgG degrading enzyme of Streptococcus
pyogenes, IdeS, has been described more recently (15, 16). The use
of IdeS enables generation of highly homogenous product by
eliminating the C-terminal heterogeneity observed from pepsin
digest (3). In certain embodiments, the F(ab').sub.2, fragments are
produced by IdeS cleavage.
C. Recombinant Methods and Compositions
[0084] Antibody fragments can be produced using recombinant methods
and compositions, e.g., as described in U.S. Pat. No. 4,816,567. In
certain embodiments, an isolated nucleic acid encoding an antibody
fragment described herein or composition comprising such nucleic
acid is provided. In addition, one or more vectors (e.g.,
expression vectors) comprising such nucleic acid are provided. A
host cell comprising such nucleic acid is also provided. In certain
embodiments, the host cell is eukaryotic, e.g. a Chinese Hamster
Ovary (CHO) cell or lymphoid cell (e.g., YO, NSO, Sp20 cell). In
certain embodiments, a method of making a Fab molecule is provided,
wherein the method comprises culturing a host cell comprising a
nucleic acid encoding the Fab, as provided above, under conditions
suitable for expression of the Fab, and optionally recovering the
Fab from the host cell (or host cell culture medium).
[0085] For recombinant production of a Fab, a nucleic acid encoding
a Fab, e.g., as described above, is isolated and inserted into one
or more vectors for further cloning and/or expression in a host
cell. Such nucleic acid can be readily isolated and sequenced using
conventional procedures (e.g., by using oligonucleotide probes that
are capable of binding specifically to genes encoding the heavy and
light chains of the Fab).
[0086] Suitable host cells for cloning or expression of
Fab-encoding vectors include prokaryotic or eukaryotic cells
described herein. For example, Fabs can be produced in bacteria.
For expression of antibody fragments, such as Fabs, in bacteria,
see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199, and 5,840,523. (See
also Charlton, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo,
ed., Humana Press, Totowa, N.J., 2003), pp. 245-254, describing
expression of antibody fragments in E. coli.) After expression, the
Fab can be isolated from the bacterial cell paste in a soluble
fraction and can be further purified.
[0087] In addition to prokaryotes, eukaryotic microbes such as
filamentous fungi or yeast are suitable cloning or expression hosts
for Fab-encoding vectors, including fungi and yeast strains whose
glycosylation pathways have been "humanized." See Gerngross, Nat.
Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech.
24:210-215 (2006).
[0088] Suitable host cells for the expression of glycosylated
proteins are also derived from multicellular organisms
(invertebrates and vertebrates). Examples of invertebrate cells
include plant and insect cells. Numerous baculoviral strains have
been identified which can be used in conjunction with insect cells,
particularly for transfection of Spodoptera frupperda cells.
[0089] Plant cell cultures can also be utilized as hosts. See,
e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978,
and 6,417,429 (describing PLANTIBODIES.TM. technology for producing
antibodies in transgenic plants).
[0090] Vertebrate cells can also be used as hosts. For example,
mammalian cell lines that are adapted to grow in suspension can be
useful. Other examples of useful mammalian host cell lines are
monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic
kidney line (293 or 293 cells as described, e.g., in Graham et al.,
J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse
sertoli cells (TM4 cells as described, e.g., in Mather, Biol.
Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African
green monkey kidney cells (VERO-76); human cervical carcinoma cells
(HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL
3A); human lung cells (W138); human liver cells (Hep G2); mouse
mammary tumor (MMT 060562); TRI cells, as described, e.g., in
Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5
cells; and FS4 cells. Other useful mammalian host cell lines
include Chinese hamster ovary (CHO) cells, including DHFR'' CHO
cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980));
and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of
certain mammalian host cell lines suitable for Fab production, see,
e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B.K.C.
Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003).
D. Pharmaceutical Formulations
[0091] Pharmaceutical formulations of an antibody fragments, e.g.,
Fab and F(ab').sub.2, as described herein, are prepared by mixing
such antibody fragment having the desired degree of purity with one
or more optional pharmaceutically acceptable carriers (Remington's
Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the
form of lyophilized formulations or aqueous solutions. For example,
but not by way of limitation, lyophilized antibody formulations are
described in U.S. Pat. No. 6,267,958. In certain embodiments,
aqueous antibody formulations can include those described in U.S.
Pat. No. 6,171,586 and WO2006/044908, the latter formulations
including a histidine-acetate buffer.
[0092] In certain embodiments, an antibody fragment of the present
disclosure can be of a purity greater than about 80%, greater than
about 90%, greater than about 91%, greater than about 92%, greater
than about 93%, greater than about 94%, greater than about 95%,
greater than about 96%, greater than about 97%, greater than about
98%, greater than about 99%, greater than about 99.1%, greater than
about 99.2%, greater than about 99.3%, greater than about 99.4%,
greater than about 99.5%, greater than about 99.6%, greater than
about 99.7%, greater than about 99.8% or greater than about
99.9%.
[0093] Pharmaceutically acceptable carriers are generally nontoxic
to recipients at the dosages and concentrations employed, and
include, but are not limited to: buffers such as phosphate,
citrate, and other organic acids; antioxidants including ascorbic
acid and methionine; preservatives (such as octadecyldimethylbenzyl
ammonium chloride; hexamethonium chloride; benzalkonium chloride;
benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl
parabens such as methyl or propyl paraben; catechol; resorcinol;
cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less
than about 10 residues) polypeptides; proteins, such as serum
albumin, gelatin, or immunoglobulins; hydrophilic polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine,
asparagine, histidine, arginine, or lysine; monosaccharides,
disaccharides, and other carbohydrates including glucose, mannose,
or dextrins; chelating agents such as EDTA; sugars such as sucrose,
mannitol, trehalose or sorbitol; salt-forming counter-ions such as
sodium; metal complexes (e.g. Zn-protein complexes); and/or
non-ionic surfactants such as polyethylene glycol (PEG). Exemplary
pharmaceutically acceptable carriers herein further include
insterstitial drug dispersion agents such as soluble neutral-active
hyaluronidase glycoproteins (sHASEGP), for example, human soluble
PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX.RTM.,
Baxter International, Inc.). Certain exemplary sHASEGPs and methods
of use, including rHuPH20, are described in US Patent Publication
Nos. 2005/0260186 and 2006/0104968. In one aspect, a sHASEGP is
combined with one or more additional glycosaminoglycanases such as
chondroitinases.
[0094] The formulation herein can also contain more than one active
ingredients as necessary for the particular indication being
treated, preferably those with complementary activities that do not
adversely affect each other. Such active ingredients are suitably
present in combination in amounts that are effective for the
purpose intended.
[0095] A composition of the present disclosure can be administered
by a variety of methods known in the art. The route and/or mode of
administration vary depending upon the desired results. The active
compounds can be prepared with carriers that protect the compound
against rapid release, such as a controlled release formulation,
including implants, transdermal patches, and microencapsulated
delivery systems. Biodegradable, biocompatible polymers can be
used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic
acid, collagen, polyorthoesters, and polylactic acid. Many methods
for the preparation of such formulations are described by e.g.,
Sustained and Controlled Release Drug Delivery Systems, J. R.
Robinson, ed., Marcel Dekker, Inc., New York, 1978. In certain
embodiments, the pharmaceutical compositions are manufactured under
Good Manufacturing Practice (GMP) conditions of the U.S. Food and
Drug Administration.
[0096] The carrier can be suitable for intravenous, intramuscular,
subcutaneous, parenteral, spinal or epidermal administration (e.g.,
by injection or infusion). Depending on the route of
administration, the active compound, i.e., antibody fragment, can
be coated in a material to protect the compound from the action of
acids and other natural conditions that can inactivate the
compound.
[0097] Active ingredients can be entrapped in microcapsules
prepared, for example, by coacervation techniques or by interfacial
polymerization, for example, hydroxymethylcellulose or
gelatin-microcapsules and poly-(methylmethacylate) microcapsules,
respectively, in colloidal drug delivery systems (for example,
liposomes, albumin microspheres, microemulsions, nano-particles and
nanocapsules) or in macroemulsions. Such techniques are disclosed
in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed.
(1980).
[0098] Sustained-release preparations can be prepared. Suitable
examples of sustained-release preparations include semipermeable
matrices of solid hydrophobic polymers containing the antibody,
which matrices are in the form of shaped articles, e.g. films, or
microcapsules.
[0099] The formulations to be used for in vivo administration are
generally sterile. Sterility can be readily accomplished, e.g., by
filtration through sterile filtration membranes.
[0100] The disclosed pharmaceutical compositions can also contain
adjuvants such as preservatives, wetting agents, emulsifying agents
and dispersing agents. Prevention of presence of microorganisms can
be ensured both by sterilization procedures, supra, and by the
inclusion of various antibacterial and antifungal agents, for
example, paraben, chlorobutanol, phenol sorbic acid, and the like.
It can also be desirable to include isotonic agents, such as
sugars, sodium chloride, and the like into the compositions. In
addition, prolonged absorption of the injectable pharmaceutical
form can be brought about by the inclusion of agents which delay
absorption such as aluminum monostearate and gelatin.
[0101] In certain embodiments, when the antibodies of the present
invention are administered as pharmaceuticals, to humans and
animals, they can be given alone or as a pharmaceutical composition
containing, for example, from about 0.01% to about 99.5% (or about
0.1 to about 90%) of an antibody fragment in combination with a
pharmaceutically acceptable carrier.
E. Therapeutic Methods and Compositions
[0102] Any of the antibody fragments provided herein can be used in
therapeutic methods. In certain embodiments, an antibody fragment
for use as a medicament is provided. In certain embodiments, an
antibody fragment for use in treating a particular disease
indication is provided. In certain embodiments, an antibody
fragment of the present disclosure can be used treat an ocular
disease and/or disorder. In certain embodiments, an antibody
fragment of the present disclosure can be used treat a disease
and/or a disorder that would benefit from the application of an
antibody fragment that exhibits a short systemic half-life. In
certain embodiments, an antibody fragment for use in a method of
treatment is provided.
[0103] In certain embodiments, the present disclosure provides an
antibody fragment for use in a method of treating an individual
having a specific disease comprising administering to the
individual an effective amount of the antibody fragment or
compositions comprising the same. In certain embodiments, the
method further comprises administering to the individual an
effective amount of at least one additional therapeutic agent,
e.g., as described below. In certain embodiments, the present
disclosure provides an antibody fragment for use in inhibiting a
particular molecular pathway and/or mechanism. In certain
embodiments, the present disclosure provides an antibody fragment
for use in a method of inhibiting a particular molecular pathway
and/or mechanism in an individual that comprises administering to
the individual an effective of the antibody fragment to inhibit the
particular molecular pathway and/or mechanism. In certain
embodiments, the present disclosure provides an antibody fragment
for use in activating a particular molecular pathway and/or
mechanism. In certain embodiments, the present disclosure provides
an antibody fragment for use in a method of activating a particular
molecular pathway and/or mechanism in an individual that comprises
administering to the individual an effective of the antibody
fragment to inhibit the particular molecular pathway and/or
mechanism. An "individual" according to any of the above
embodiments can be a human.
[0104] In certain embodiments, the present disclosure provides for
the use of an antibody fragment in the manufacture or preparation
of a medicament. In certain embodiments, the medicament is for
treatment of a particular disease. In certain embodiments, the
medicament is for use in a method of treating a particular disease
comprising administering to an individual having the disease an
effective amount of the medicament. In certain embodiments, the
method further comprises administering to the individual an
effective amount of at least one additional therapeutic agent,
e.g., as described below. In certain embodiments, the medicament is
for inhibiting or activating a particular molecular pathway and/or
mechanism. In certain embodiments, the medicament is for use in a
method of inhibiting or activating a particular molecular pathway
and/or mechanism in an individual comprising administering to the
individual an amount effective of the medicament to inhibit a
particular molecular pathway and/or mechanism. An "individual"
according to any of the above embodiments can be a human.
[0105] In certain embodiments, the present disclosure provides a
method for treating a particular disease. In certain embodiments,
the method comprises administering to an individual having such
disease an effective amount of an antibody fragment. In certain
embodiments, the method further comprises administering to the
individual an effective amount of at least one additional
therapeutic agent, as described below. An "individual" according to
any of the above embodiments can be a human.
[0106] In certain embodiments, the present disclosure provides a
method for inhibiting a particular molecular pathway and/or
mechanism in an individual. In certain embodiments, the method
comprises administering to the individual an effective amount of an
antibody fragment to inhibit a particular molecular pathway and/or
mechanism. In certain embodiments, an "individual" is a human.
[0107] In certain embodiments, the present disclosure provides
pharmaceutical formulations comprising any of the antibody
fragments provided herein, e.g., for use in any of the above
therapeutic methods. In certain embodiments, a pharmaceutical
formulation comprises any of the antibody fragments provided herein
and a pharmaceutically acceptable carrier. In certain embodiments,
a pharmaceutical formulation comprises any of the antibody
fragments provided herein and at least one additional therapeutic
agent, e.g., as described below.
[0108] Antibody fragments of the present disclosure can be used
either alone or in combination with other agents in a therapy. For
instance, an antibody fragment of the present disclosure can be
co-administered with at least one additional therapeutic agent.
[0109] Such combination therapies noted above encompass combined
administration (where two or more therapeutic agents are included
in the same or separate formulations), and separate administration,
in which case, administration of the antibody of the present
disclosure can occur prior to, simultaneously, and/or following,
administration of the additional therapeutic agent or agents. In
certain embodiments, administration of the antibody fragment and
administration of an additional therapeutic agent occur within
about one month, or within about one, two or three weeks, or within
about one, two, three, four, five, or six days, of each other. The
antibody fragments described herein can also be used in combination
with radiation therapy.
[0110] An antibody fragment (and any additional therapeutic agent)
can be administered by any suitable means, including parenteral,
intrapulmonary, intraocular, and intranasal, and, if desired for
local treatment, intralesional administration. Parenteral infusions
include intramuscular, intravenous, intraarterial, intraocular,
intraperitoneal, or subcutaneous administration. Dosing can be by
any suitable route, e.g. by injections, such as intravenous or
subcutaneous injections, depending in part on whether the
administration is brief or chronic. Various dosing schedules
including but not limited to single or multiple administrations
over various time-points, bolus administration, and pulse infusion
are contemplated herein.
[0111] Antibody fragments are formulated, dosed and administered in
a fashion consistent with good medical practice. Factors for
consideration in this context include the particular disease being
treated, the particular mammal being treated, the clinical
condition of the individual patient, the cause of the disease, the
site of delivery of the agent, the method of administration, the
scheduling of administration, and other factors known to medical
practitioners. The antibody fragment need not be, but is optionally
formulated with one or more agents currently used to prevent or
treat the disease in question. The effective amount of such other
agents depends on the amount of antibody fragment present in the
formulation, the type of disease or treatment, and other factors
discussed above. These are generally used in the same dosages and
with administration routes as described herein, or about from 1 to
99% of the dosages described herein, or in any dosage and by any
route that is empirically/clinically determined to be
appropriate.
[0112] For the prevention or treatment of disease, the appropriate
dosage of an antibody fragment of the present disclosure (when used
alone or in combination with one or more other additional
therapeutic agents) will depend on the type of disease to be
treated, the type of antibody fragment, the severity and course of
the disease, whether the antibody fragment is administered for
preventive or therapeutic purposes, previous therapy, the patient's
clinical history and response to the antibody fragment, and the
discretion of the attending physician. The antibody fragment is
suitably administered to the patient at one time or over a series
of treatments. Depending on the type and severity of the disease,
about 1 .mu.g/kg to 15 mg/kg (e.g. 0.1 mg/kg-10 mg/kg) of antibody
fragment can be an initial candidate dosage for administration to
the patient, whether, for example, by one or more separate
administrations, or by continuous infusion. One typical daily
dosage might range from about 1 .mu.g/kg to 100 mg/kg or more,
depending on the factors mentioned above. For repeated
administrations over several days or longer, depending on the
condition, the treatment would generally be sustained until a
desired suppression of disease symptoms occurs. One exemplary
dosage of the antibody fragment would be in the range from about
0.05 mg/kg to about 10 mg/kg. Thus, one or more doses of about 0.5
mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination
thereof) can be administered to the patient. Such doses can be
administered intermittently, e.g. every week or every three weeks
(e.g., such that the patient receives from about two to about
twenty, or e.g., about six doses of the antibody fragment). An
initial higher loading dose, followed by one or more lower doses
can be administered. The progress of this therapy is easily
monitored by conventional techniques and assays.
[0113] It is understood that any of the above formulations or
therapeutic methods can be carried out using an immunoconjugate in
place of or in addition to an antibody fragment of the present
disclosure.
F. Immunoconjugates
[0114] The presently disclosed subject matter also provides
immunoconjugates, which include an antibody fragment, disclosed
herein, conjugated to one or more cytotoxic agents, such as
chemotherapeutic agents or drugs, growth inhibitory agents,
proteins, peptides, toxins (e.g., protein toxins, enzymatically
active toxins of bacterial, fungal, plant, or animal origin, or
fragments thereof), or radioactive isotopes. For example, an
antibody fragment of the disclosed subject matter can be
functionally linked (e.g., by chemical coupling, genetic fusion,
noncovalent association or otherwise) to one or more other binding
molecules, such as another antibody, antibody fragment, peptide or
binding mimetic.
[0115] In certain embodiments, an immunoconjugate is an
antibody-drug conjugate (ADC) in which an antibody fragment is
conjugated to one or more drugs, including but not limited to, a
maytansinoid (see U.S. Pat. Nos. 5,208,020, 5,416,064 and European
Patent EP 0 425 235 B1); an auristatin such as monomethylauristatin
drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. Nos.
5,635,483 and 5,780,588, and 7,498,298); a dolastatin; a
calicheamicin or derivative thereof (see U.S. Pat. Nos. 5,712,374,
5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001,
and 5,877,296; Hinman et al., Cancer Res. 53:3336-3342 (1993); and
Lode et al., Cancer Res. 58:2925-2928 (1998)); an anthracycline
such as daunomycin or doxorubicin (see Kratz et al., Current Med.
Chem. 13:477-523 (2006); Jeffrey et al., Bioorganic & Med.
Chem. Letters 16:358-362 (2006); Torgov et al., Bioconj. Chem.
16:717-721 (2005); Nagy et al., Proc. Natl. Acad. Sci. USA
97:829-834 (2000); Dubowchik et al., Bioorg. & Med. Chem.
Letters 12:1529-1532 (2002); King et al., J. Med. Chem.
45:4336-4343 (2002); and U.S. Pat. No. 6,630,579); methotrexate;
vindesine; a taxane such as docetaxel, paclitaxel, larotaxel,
tesetaxel, and ortataxel; a trichothecene; and CC1065.
[0116] In certain embodiments, an immunoconjugate includes an
antibody fragment as described herein conjugated to an
enzymatically active toxin or fragment thereof, including but not
limited to diphtheria A chain, nonbinding active fragments of
diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa),
ricin A chain, abrin
[0117] A chain, modeccin A chain, alpha-sarcin, Aleurites fordii
proteins, dianthin proteins, Phytolaca americana proteins (PAPI,
PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin,
sapaonaria officinalis inhibitor, gelonin, mitogellin,
restrictocin, phenomycin, enomycin, and the tricothecenes. In
certain embodiments, an immunoconjugate includes an antibody
fragment, as described herein, conjugated to a radioactive atom to
form a radioconjugate. A variety of radioactive isotopes are
available for the production of radioconjugates. Non-limiting
examples include At.sup.211, I.sup.131, I.sup.125, Y.sup.90,
Re.sup.186, Re.sup.188, Sm.sup.153, Bi.sup.212, P.sup.32,
Pb.sup.212 and radioactive isotopes of Lu. When a radioconjugate is
used for detection, it can include a radioactive atom for
scintigraphic studies, for example tc99m or I.sup.123, or a spin
label for nuclear magnetic resonance (NMR) imaging (also known as
magnetic resonance imaging, mri), such as iodine-123, iodine-131,
indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17,
gadolinium, manganese or iron.
[0118] Conjugates of an antibody fragment and cytotoxic agent can
be made using a variety of bifunctional protein coupling agents
such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP),
succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate
(SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters
(such as dimethyl adipimidate HCl), active esters (such as
disuccinimidyl suberate), aldehydes (such as glutaraldehyde),
bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine),
bis-diazonium derivatives (such as
bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as
toluene 2,6-diisocyanate), and bis-active fluorine compounds (such
as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin
immunotoxin can be prepared as described in Vitetta et al., Science
238:1098 (1987). Carbon-14-labeled
1-isothiocyanatobenzyl-3-methyldiethyl ene triaminepentaacetic acid
(MX-DTPA) is an exemplary chelating agent for conjugation of
radionucleotide to the antibody. See WO 94/11026. The linker can be
a "cleavable linker" facilitating release of a cytotoxic drug in
the cell. For example, an acid-labile linker, peptidase-sensitive
linker, photolabile linker, dimethyl linker or disulfide-containing
linker (Chari et al., Cancer Res. 52:127-131 (1992); U.S. Pat. No.
5,208,020) can be used. Non-limiting examples of linkers are
disclosed above.
[0119] The immunuoconjugates disclosed herein expressly
contemplate, but are not limited to such conjugates prepared with
cross-linker reagents including, but not limited to, BMPS, EMCS,
GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH,
sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-STAB,
sulfo-SMCC, and sulfo-SMPB, and SVSB
(succinimidyl-(4-vinylsulfone)benzoate) which are commercially
available (e.g., from Pierce Biotechnology, Inc., Rockford, Ill.,
U.S.A).
G. Articles of Manufacture
[0120] In certain embodiments of the present disclosure, an article
of manufacture containing materials useful for the treatment,
prevention and/or diagnosis of the disorders described above is
provided. The article of manufacture comprises a container and a
label or package insert on or associated with the container.
Suitable containers include, for example, bottles, vials, syringes,
IV solution bags, etc. The containers can be formed from a variety
of materials such as glass or plastic. The container holds a
composition which is by itself or combined with another composition
effective for treating, preventing and/or diagnosing the condition
and can have a sterile access port (for example the container can
be an intravenous solution bag or a vial having a stopper
pierceable by a hypodermic injection needle). At least one active
agent in the composition is an antibody fragment of the present
disclosure. The label or package insert indicates that the
composition is used for treating the condition of choice. Moreover,
the article of manufacture can comprise (a) a first container with
a composition contained therein, wherein the composition comprises
an antibody fragment of the present disclosure; and (b) a second
container with a composition contained therein, wherein the
composition comprises a further cytotoxic or otherwise therapeutic
agent. The article of manufacture in this embodiment of the present
disclosure can further comprise a package insert indicating that
the compositions can be used to treat a particular condition.
Alternatively, or additionally, the article of manufacture can
further comprise a second (or third) container comprising a
pharmaceutically-acceptable buffer, such as bacteriostatic water
for injection (BWFI), phosphate-buffered saline, Ringer's solution
and dextrose solution.
[0121] It can further include other materials desirable from a
commercial and user standpoint, including other buffers, diluents,
filters, needles, and syringes.
[0122] It is understood that any of the above articles of
manufacture can include an immunoconjugate in place of or in
addition to an antibody fragment as described herein.
III. EXAMPLES
[0123] The following are examples of the methods and compositions
of the present disclosure. It is understood that various other
embodiments can be practiced, given the general description
provided above.
Example 1
Evading the Pre-existing Anti-Hinge Antibody Response by Hinge
Engineering
[0124] Fab and F(ab').sub.2 antibody fragments serve as alternative
formats to full-length antibodies in therapeutic and immune assays.
They provide the advantage of small size, short serum half-life,
and lack of effector function. Several proteases associated with
invasive diseases are known to cleave antibodies in the
hinge-region and result in anti-hinge antibodies (AHA) towards the
neoepitopes. Pre-existing AHA in serum can act as surrogate Fc and
reintroduce the properties of the Fc lacking in antibody fragments.
While this response is desired during the natural process of
fighting disease, it is commonly unwanted for therapeutic antibody
fragments. In this study, a truncation in the lower hinge region of
the antibody that maintains efficient proteolytic cleavage by IdeS
protease was identified. The resulting neoepitope at the
F(ab').sub.2 C-terminus did not have detectable pre-existing AHA,
providing a practical route to produce F(ab').sub.2 in vitro by
proteolytic digestion when pre-existing AHA response is undesired.
In this study, the upper hinge region of the antibody was also
studied, which provided a detailed analysis of the contribution of
C-terminal residues of the upper hinge of human IgG1, IgG2 and IgG4
to pre-existing AHA reactivity in human serum. While no
pre-existing antibodies were observed towards the Fab of IgG2 and
IgG4 isotype, a significant response was observed towards most
residues of the upper hinge of human IgG1. A T.sub.225L mutation
(also referred to herein as the "T225L variant") and the natural
C-terminal D.sub.221 were identified as solutions with minimal
serum reactivity. This study enabled the production of Fab and
F(ab').sub.2 fragments for therapeutic and immune assays that have
minimal reactivity towards pre-existing AHA. [0125] Materials and
Methodsa
[0126] Plasmid construction and antibody expression: Antibodies
were cloned by standard molecular biology techniques into E. coli
expression vectors (9, 23) or mammalian expression vectors (24) as
previously described. E. coli expression was carried out as
described in Simmons et al. (23). IgG and Fab was expressed in 30
mL transient transfection cultures of CHO (25) or HEK293T (26)
cells as previously described.
[0127] Cloning, expression, and purification of IdeS: IdeS was
expressed as N-terminal glutathione S-transferase (GST) fusion
protein. The mature sequence of IdeS from Streptococcus pyogenes
MGAS1882 (Uniprot ID H8HDRO) was codon optimized for E. coli
expression and synthesized by GeneArt.TM. and cloned by standard
molecular biology techniques into E. coli expression vector (23).
IdeS was expressed using conditions described in Simmons et al.
(23) and purified using glutathione sepharose (GSH) column. Eluate
fractions in 50mM Tris-HCl, pH 8.0, 20 mM glutathione from the GSH
column were concentrated and loaded onto S200 column and eluted
with 200 mM K.sub.2HPO.sub.4, pH 6.2, 250mM KCl.
[0128] Antibody and Fab purification: After expression, the cells
were pelleted by gravity. The supernatants were transferred to a 50
ml Falcon tube (Corning, Corning, N.Y., USA). 400 .mu.l of 50%
MabSelect SuRe.TM. protein affinity slurry or Gamma Bind.TM. Plus
slurry (GE Healthcare, Pittsburgh, Pa., USA) was added to the
supernatants for IgG and Fab purification respectively. The mixture
was incubated overnight at room temperature on an Innova 2000
platform shaker (New Brunswick Scientific, Enfield, Conn., USA).
Supernatants were removed and the resin transferred to a 96-well 2
ml filter plate with a 25 .mu.m size membrane (Thompson Instrument,
Oceanside, Calif., USA). The resin was washed three times with 1 ml
of 1.times. PBS pH 7.4 by centrifugation at 1,120.times. g for 5
minutes using a Sorvall.TM. HT6 Centrifuge (Thermo Scientific,
Waltham, Mass., USA). For Fab purification the resin was further
washed with 0.2.times. PBS pH 5.0 before elution. The IgG was
eluted using 50 mM phosphoric acid pH 2.9 and the eluate
neutralized with 20.times. PBS pH 11.0 by centrifugation at
1,000.times. g for 5 minutes. The Fab fragments were eluted using
10 mM sodium citrate pH 2.9 and neutralized with 0.3 M Tris pH 9.0.
The eluted IgG and Fab was filtered through 0.2 .mu.m 96-well
filter plate (Orochem, Naperville, Ill., USA) by centrifugation at
1,000.times. g for 5 minutes using an Sorvall HT6 Centrifuge
(Thermo Scientific, Waltham, Mass., USA).
[0129] IdeS digestion of IgG hinge variants: IgG at 1 mg/ml was
incubated with stated IdeS:IgG ratio (w/w) at 37.degree. C. for 24
hours. For scaled up digestion to generate highly pure F(ab').sub.2
material in large quantities for AHA assays, up to 1:10 IdeS:IgG
ratio was used to drive complete digestion.
[0130] F(ab').sub.2 purification after IgG cleavage by IdeS: The
IdeS cleaved sample was diluted with 25 mM Sodium Acetate, pH 4.4
(Buffer A) and loaded onto a 1 mL SP Sepharose High Performance
strong cation exchange column (GE Healthcare, Pittsburgh, Pa., USA)
at 150 cm/hr (0.7 cm diameter, 10 cm bed height) equilibrated in
Buffer A. The column was washed to baseline with Buffer A and
F(ab').sub.2 eluted with a linear salt gradient from 0 to 0.5 M
NaCl over 30 column volumes. The eluate was neutralized by addition
of 3 M Tris pH 9.0 to adjust the pH to 7.0 and filtered through
0.22 .mu.m STERIFLIP.RTM. (EMD Millipore, Billerica, Mass., USA).
The SP eluted F(ab').sub.2 was further purified on a MonoS 5/50 GL
strong cation exchange column (GE Healthcare, Pittsburgh, Pa., USA)
after diluting with Buffer A to lower the conductivity <5 mS/cm.
The column was washed to baseline (<0.05 mAU) with Buffer A and
the F(ab').sub.2 eluted using a salt gradient from 0 to 0.6 M NaC1
over 40 column volumes. The eluted F(ab').sub.2 solution was
neutralized with 3 M Tris pH 9.0 to adjust the pH to 7.0 and
filtered through 0.22 .mu.m STERIFLIP.RTM. (EMD Millipore,
Billerica, Mass., USA).
[0131] Mass spectrometry of Fab and F(ab').sub.2 fragments: Mass
spectrometric data was acquired using an Agilent 6224 TOF LC-MS
system (Agilent Technology, Santa Clara, Calif., USA). F(ab').sub.2
was reduced with 100 mM dithiothreitol at 37.degree. C. for 20
minutes. The polypeptide chains were separated with a PLRP-S
reversed phase column (Agilent Technologies, Santa Clara, Calif.,
USA). Intact masses of the reduced light and heavy chains were
obtained by Maximun Entropy Deconvolution using MassHunter software
(Qualitative Analysis B.03.01).
[0132] Analysis of protein by capillary electrophoresis: All
samples were prepared by mixing 5 .mu.l of sample volume with 7
.mu.l of HT Protein Express Sample buffer and incubated for 5
minutes at 70.degree. C. 32 .mu.l of water was added to the samples
and centrifuged at 1,000.times. g for 5 minutes. The chip was
prepared according to manufacturer's instructions provided in the
LabChip GXII User Guide and samples were analyzed on a Caliper GX
II microfluidic system (PerkinElmer.RTM. Biotechnology, Waltham,
Mass., USA). Samples were analyzed on a Caliper GXII microfluidic
system (PerkinElmer.RTM. Biotechnology, Waltham, Mass., USA). All
reagents were obtained from PerkinElmer.RTM..
[0133] Pre-existing anti-hinge antibody enzyme-linked immunosorbent
assay (ELISA): MAXISORP.RTM. plates (384-well, Nunc, Thermo Fisher
Scientific, Rochester, NY, USA) were coated with 1 .mu.g/m1
F(ab').sub.2 or Fab in 50 mM carbonate, pH 9.6 at 4.degree. C.
overnight. Plates were washed with 0.05% polysorbate 20 in PBS, pH
7.4 and then blocked with 0.5% BSA, 15 ppm proclin in PBS, pH 7.4.
Pooled human serum from 25 female and 25 male individuals
(BioreclamationlVT, Westbury, N.Y., USA) were serially diluted in
assay buffer (0.5% BSA, 0.05% polysorbate 20, 15 ppm PROCLIN.TM.,
in PBS, pH 7.4) and added to the plates. After a 2 hour incubation,
bound pre-existing anti-hinge antibody was detected using
horseradish peroxidase (HRP) goat anti-F(ab').sub.2 conjugated
anti-human IgG Fc (Jackson ImmunoResearch, West Grove, Pa.) in
assay buffer, followed by 3,3',5,5'-tetramethyl benzidine (TMB,
Moss Inc., Pasadena, Md., USA) as the substrate. The reaction was
stopped with 1 M phosphoric acid and absorbance was read at 450 nm.
The absorbance readings at 1:30 dilution were used for the figures
to allow presentation of all samples. Comparable results were
observed at a 1:10 serum dilution. To calculate the relative AHA
reactivity, the titration curve of F(ab').sub.2 was fitted with a 4
parameter curve fitting program (KaleidaGraph, Synerg Software,
Reading, Pa.). MidOD (the average OD of the top and bottom OD
readings) of the F(ab').sub.2 titration curve was determined. The
dilutions of Fab DKTHT (SEQ ID NO: 21) and F(ab').sub.2
corresponding to this midOD were calculated and used to calculate
the relative AHA reactivity.
[0134] SDS-PAGE and immunoblots: For SDS-PAGE, 5.mu.g of purified
F(ab').sub.2 variants and GST-IdeS were mixed with SDS-sample
buffer, heated for 5 min at 95.degree. C. and spun for 1 min at
16,000 relative centrifugal force. The samples were loaded onto a
NuPAGE 4-12% BisTris/MES gels (Invitrogen). For immunoblotting, 5
ng of protein samples were used for SDS-PAGE. Gels were transferred
by IBLOT.RTM. (Invitrogen) onto nitrocellulose membrane,
immunoblotted with anti-IdeS (Genovis, USA; catalog no. A3-AF1-010,
lot no. A3AF1-7C17H) as primary antibody and IRDye800CW conjugated
donkey anti-goat antibody (Li-COR.RTM., USA; catalog no. 926-32214,
lot no. B80821-03) as the secondary antibody, and imaged with a
LI-COR.RTM. Odyssey.RTM. Imager (LI-COR.RTM., USA). Odyssey.RTM.
Two-color protein molecular weight marker (LI-COR.RTM., USA) was
used for immunoblots and pre-stained SEEBLUE.RTM. Plus2
(Invitrogen, USA) was used for Coomassie stained gels.
[0135] Protein stability measurements by differential scanning
fluorimetry: Protein stability was determined in a Biorad CFX96
TOUCH.TM. Real-Time System (Biorad, USA) with a final dilution of
1:200 of the SYPRO.RTM. Orange dye stock (Molecular Probes.TM.,
USA). 1.mu.l of the SYPRO.RTM. Orange dye stock was added to 24
.mu.l of the purified antibody at 100 .mu.g/ml. Fluorescence of the
final 25 .mu.l sample in PBS was recorded from 20-100.degree. C.
(0.2.degree. C. increments, 10 seconds hold per step). [0136]
Results
[0137] Fab C-terminus determines response to pre-existing AHA:
Originally, reactivity of autoantibodies in human serum towards the
upper hinge of Fab molecules was studied with a papain cleaved
antibody, abciximab (5). Papain cleavage leaves a C-terminal
H.sub.224 on the Fab. Later, a more comprehensive study was carried
out using biotinylated peptide analogs to dissect the contribution
of individual C-terminal residues of the upper hinge (20). In this
study, only minimal AHA reactivity towards the upper hinge residues
K.sub.222 through H.sub.224 was observed. No signal was observed
towards peptides with T.sub.225 as the C-terminal residue. The use
of synthetic peptides can confound results because the Fab-tail
spanning the upper hinge residues D.sub.221 to T.sub.225 (FIG. 1A)
is presented outside of the context of the intact molecule. Thus,
the Fab-tail contribution for binding to pre-existing AHA in the
setting of an intact Fab was studied.
[0138] The recombinant expression of Fab molecules in E. coli and
mammalian cells allows to readily produce molecules with defined
C-terminal ends without the need of proteolytic cleavage. To ensure
integrity of the C-terminus, correct mass of the purified Fab was
confirmed by intact mass-spectrometry. The Fab molecules were
coated on microtiter plates, and after incubation with pooled human
donor serum, binding of pre-existing AHA was quantified by anti-Fc
detection. In agreement with the previous study (20), T.sub.223 at
the C-terminus (having the sequence DKT, also referred to herein as
"CDKT" (SEQ ID NO: 17)) showed the highest reactivity of all upper
hinge variants towards pre-existing AHA (FIG. 1B). Significant
difference to the previous studies is observed with T.sub.225 at
the C-terminus (having the sequence DKTHT (SEQ ID NO: 21), also
referred to herein as "CDKTHT" (SEQ ID NO: 14)). This variant did
not bind AHA as peptide (20); however, substantial AHA reactivity
was observed when tested as Fab. With D.sub.221 at the C-terminus
(having the sequence D, also referred to herein as "CD"), binding
of AHA was reduced almost to background. Thus, terminating the Fab
at D.sub.221 provides a solution to minimize recognition by
pre-existing AHA while maintaining a natural antibody sequence.
[0139] As demonstrated by these experiments, the C-terminal Fab
residue has a profound impact on AHA binding. Whether binding by
pre-existing antibodies could also be obviated by a single amino
acid change at the C-terminus and provide an alternative route to
the D.sub.221 to minimize reactivity towards AHA was investigated.
A T.sub.225L variant was introduced to place a non-natural residue
at the Fab C-terminus, and its binding of AHA was tested. The
T.sub.225L variant has been described previously (7). The mutation
perturbed binding of the pre-existing AHA (FIG. 1B), further
highlighting the importance of the C-terminus for binding. To
exclude the possibility that the reduced AHA in T.sub.225L was due
to reduced coating efficiency, an antigen capture format was used
to capture the Fab molecules, and a similar fold of AHA signal
reduction was also observed. To determine whether this observation
can be generalized, three different Fabs were incubated with pooled
human serum and binding of pre-existing antibodies was detected by
ELISA. Significant signal was observed for the three different Fabs
having a DKTHT (SEQ ID NO: 21) C-terminus while reduced binding of
pre-existing antibodies to the D.sub.221 and T.sub.225L C-terminus
was indeed detected. (FIG. 1C).
[0140] Next, Fab molecules of IgG2 and IgG4 isotypes were studied.
While IgG1, IgG2 and IgG4 are commonly used for therapeutic
antibodies, the use of IgG2 and IgG4 Fabs has not been leveraged
for therapeutic development so far. Thus, IgG2 and IgG4 Fabs with
the complete upper hinge region (FIG. 1D; C-terminus K.sub.218 and
P.sub.225, respectively) were tested. In contrast to IgG1 Fab, the
IgG2 and IgG4 Fabs were not recognized by pre-existing AHA. Next,
the upper hinge of the IgG4 was truncated. The length of the IgG4
isotype upper hinge is shorter when compared to IgG1 (see FIG.
6A-B); however, since the cysteine involved in the heavy-light
interchain disulfide is located in the center of the C.sub.H1
primary structure, it was able to include residues K.sub.218 and
Y.sub.219 in the truncation experiments. These truncated upper
hinge Fabs displayed a signal similar to the intact IgG1 upper
hinge (FIG. 1B).
[0141] All Fab molecules within the same isotype yielded similar
expression levels in E. coli and CHO (FIG. 7). No change in thermal
stability was observed within the same isotype (Table 3). Thermal
stability of IgG2 and IgG4 Fabs was decreased by about 6.degree. C.
compared to IgG1 isotype.
[0142] In conclusion, multiple Fab formats with minimal reactivity
towards pre-existing AHA exist: IgG1-D.sub.221, IgG1-T.sub.225L,
IgG2 and IgG4.
TABLE-US-00003 TABLE 3 Thermal Stability of T30M Fab determined by
differential scanning fluorimetry Human isotype C-terminus Tm
(.degree. C.) IgG1 ..DKTHL (SEQ ID NO: 20) 81.6 ..DKTHT (SEQ ID NO:
21) 81.8 ..DKTH (SEQ ID NO: 27) 81.7 ..DKT 81.8 ..DK 81.7 ..D 81.9
IgG2 ..K 75.5 IgG4 ..KYGPP (SEQ ID NO: 18) 75.9 ..KYG 75.7 ..KY
75.8 ..K 75.6
[0143] IgG1 with the lower hinge of IgG2 cannot be cleaved
efficiently: Pre-existing AHA towards the lower hinge region of
F(ab').sub.2 have been extensively described in the literature (13,
27). Analogous to the AHA to the upper hinge of Fab molecules,
these AHA can act as surrogate Fc or introduce assay artifacts.
Thus, development of a F(ab').sub.2 format that impedes AHA binding
is desirable. While AHA in serum are found towards F(ab').sub.2 of
IgG1 isotype, it has not been possible to establish existence of
autoantibodies to the lower hinge of IgG2 isotype. Interestingly,
the lack of such autoantibodies coincides with the inability of
physiologically relevant human proteases to efficiently cleave IgG2
into F(ab').sub.2 fragments (28). However, inefficient cleavage of
IgG2 has been observed using IdeS protease (28). IdeS is an IgG
specific endoprotease from Streptococcus pyrogenes that cleaves
after G236. In addition to the cleavage site in the antibody hinge
region, it recognizes a second site in the Fc that contributes to
its high specificity towards IgG (15, 16). The inefficient cleavage
of IgG2 antibodies could be caused by the exosite outside of the
cleavage site. Thus, the lower hinge residues of IgG2 were grafted
onto IgG1 to create an IgG1-2 chimera (FIG. 2B). The cleavage
efficiency at different IdeS:IgG ratios was tested (FIG. 2C). While
IgG1 wild-type was efficiently cleaved into F(ab').sub.2 at a
IdeS:IgG ratio of 1:500, at least 50-fold higher protease
concentration was necessary to achieve similar cleavage of the
IgG1-2 chimera. It was concluded that the sequence differences in
the lower hinge at least partially contribute to the poor cleavage
efficiency of IgG2 antibodies. Thus, the IgG1-2 chimera may not be
a practical strategy to generate F(ab').sub.2 molecules that do not
bind to pre-existing AHA.
[0144] Characterizing the P1 and P2 positions for efficient IdeS
cleavage: It was demonstrated that binding of pre-existing AHA can
be prevented by a single C-terminal T.sub.225L mutation with the
Fab experiments described. A similar strategy was employed for the
F(ab').sub.2. As a first step, residues in the P1 (EU236) and P2
(EU235) site that allow cleavage by IdeS protease were identified.
A set of 76 Fab variants that included L.sub.235, L.sub.235V,
L.sub.2351, or L.sub.235M at the P2 position for IdeS were
generated and combined with any amino acid except cysteine in P1
(FIG. 3D and E). The antibodies were purified and digested with
IdeS at an IdeS:IgG ratio of 1:10 to identify variants that can be
cleaved by IdeS. Such high protease to antibody ratio was chosen to
assess proteolysis without taking cleavage efficiency into account.
Seven variants were identified that were cleaved by IdeS (FIG. 3A).
While the P2 position tolerated all four residues tested, only two
amino acids with very small side chains, the natural glycine and
alanine, were accepted in the P1 position. This subset was further
investigated for cleavage efficiency at three different IdeS:IgG
ratios: 1:500, 1:200 and 1:100 (FIG. 3B) and 1:10 (FIG. 3C). The
variant L.sub.235V in the P2 position demonstrated minimal change
in cleavage efficiency compared to the wild-type sequence. All
other variants were characterized by a dominant single cleavage at
only one side of the hinge, leaving the other side of the antibody
intact. While L.sub.2351 and L.sub.235M variants with glycine in
the P1 position could be completely cleaved at IdeS:IgG ratio of
1:200, all P2 variants with alanine in P1 needed significantly
higher protease amounts. Hence, efficient cleavage by IdeS requires
glycine in the P1 position.
[0145] C-terminal F(ab').sub.2 variants do not prevent recognition
by pre-existing AHA: IdeS can confound results of the pre-existing
AHA assay with a false positive result. This can be explained by
binding of serum antibodies by IdeS and their subsequent
recognition by the anti-Fc detection antibody. Therefore, it was
ensured that F(ab').sub.2 molecules used in the assay did not
contain IdeS from the preceding proteolysis reaction. The removal
of IdeS in the purified F(ab').sub.2 proteins was confirmed by
SDS-PAGE followed by Coomassie staining and anti-IdeS immunoblot
(FIG. 4A). The purified P1 and P2 F(ab').sub.2 variants were then
tested for their recognition to pre-existing AHA (FIG. 4B). While
there was a reduction of signal compared to the wild-type, none of
the antibodies with C-terminal modifications eliminated the
reactivity with serum autoantibodies. Changes to the P2 position
only had a modest impact. The G.sub.236A change in the P1 position
reduced the signal to levels comparable to a Fab. Without being
limited to a particular theory, it is thus not possible to design a
lower hinge with an amino acid variant that retains cleavage by
IdeS and concurrently eliminates pre-existing antibody response
against the F(ab').sub.2.
[0146] Deletions in the lower hinge prevents recognition by
pre-existing AHA while retaining IdeS cleavage: Another strategy
was employed to remove the epitope of the AHA by truncating the
lower hinge. Leaving the P1 (EU236) and P2 (EU235) residues
untouched for their significance in cleavage efficiency, single and
double residue deletions in the P3 (EU234), P4 (EU233) and P5
(EU232) sites of IdeS were generated to identify residues with a
minimal impact in cleavage efficiency (see FIG. 5F). Significantly
poor cleavage efficiency was observed with deletion of the P3
position, thus this position was not considered for further studies
(FIG. 5A). Antibodies with deletions of P4, P5 and a combination of
both (.DELTA.P45; also referred to herein as a deletion of amino
acid residues at positions EU232-233) were tested for binding to
AHA (FIG. 5B). For these variants, a lower signal was observed
compared to the wild-type hinge sequence. To further reduce hinge
recognition by pre-existing AHA, the deletion was extended to
include the P6 (EU231) and P7 (EU230) residues (see FIG. 5F). While
the deletion of P4 through P7 sites (AP4567; also referred to
herein as a deletion of amino acid residues at positions EU230-233)
resulted in modestly reduced cleavage efficiency, the deletion of
P4 through P6 sites (AP456; also referred to herein as a deletion
of amino acid residues at positions EU231-233) had cleavage
efficiency comparable to wild-type at IdeS:IgG ratio of 1:200 (FIG.
5C and FIG. 8). Both variants did not result in pre-existing AHA
recognition (FIG. 5D). To ensure high cleavage specificity of IdeS
is maintained, ESI-TOF mass spectrometry was used to analyze the
IdeS cleaved F(ab').sub.2. Only a single mass corresponding to the
expected cleavage site at G.sub.236 was observed for the
F(ab').sub.2 from the wild-type as well as the .DELTA.P456 variant
F(ab').sub.2 (FIG. 5E).
[0147] As shown in FIG. 11, the observed AHA binding signal of the
.DELTA.P456 variant F(ab').sub.2 is comparable to the two Fab
C-terminal variants, Fab D.sub.221 and Fab T.sub.225L. The
dilutions corresponding to the OD (1.15) at the middle of the
F(ab').sub.2 titration curves were 70 and 14 for F(ab').sub.2 and
Fab, respectively. Without being limited to a particular theory,
the five-fold higher AHA activity seen with F(ab').sub.2 compared
to Fab T.sub.225 can be explained by the potential bivalent binding
of AHA to the F(ab').sub.2, which indicates that F(ab').sub.2
molecules need avoid pre-existing AHA. To exclude the possibility
that the reduced AHA reactivity seen in F(ab').sub.2 .DELTA.P456
and Fab T.sub.225L was due to reduced coating efficiency, an
antigen capture format was used to detect AHA. The OD readings
(n=4) were 2.2.+-.0.1, 0.34.+-.0.03, 1.3.+-.0.1, 0.36.+-.0.02 and
0.32.+-.0.01 on antigen coated wells receiving F(ab').sub.2,
.DELTA.P456 F(ab').sub.2, Fab, Fab T.sub.225L and buffer at 1:30
serum dilution, respectively. Thus, these results confirmed that
.DELTA.P456 F(ab').sub.2 and Fab T.sub.225L had reduced AHA
reactivity compared to their corresponding wild type molecules.
[0148] These data show that the .DELTA.P456 variant provides a
solution to avoid pre-existing AHA response towards the lower hinge
of F(ab').sub.2 while maintaining the possibility to produce the
F(ab').sub.2 antibody fragment by the well-established route of
proteolytic digest.
[0149] Deletions in the lower hinge in C-terminal F(ab').sub.2
variants: The C-terminal variants having deletions in the lower
hinge region were analyzed to determine whether the recognition by
pre-existing AHA were altered. A set of 6 variants that included
L.sub.235, L.sub.235V, L.sub.235I, or L.sub.235M at the P2 position
for IdeS with alanine or glycine at P1 were generated with various
hinge region deletions (FIG. 9). This subset was further
investigated for cleavage efficiency at three different IdeS:IgG
ratios: 1:10 (FIG. 9A), 1:100 (FIG. 9B) and 1:500 (FIG. 9C). As
shown in FIG. 9D, the variant L.sub.235V or G.sub.236A in
combination with a deletion at P5, resulted in a reduced AHA signal
compared to the deletion of P5 alone. As shown in FIG. 10, the
.DELTA.P456 variant that included L.sub.235V, L.sub.235I, or
L.sub.235M at P2 position with alanine or glycine in P1 exhibited
similar reductions in AHA signal compared to .DELTA.P456 alone
(FIG. 10B); however, the deletion of .DELTA.P456 alone exhibited
better cleavage efficiency compared to the variants in combination
with .DELTA.P456 (FIG. 10A). [0150] Discussion
[0151] Antibody fragments such as Fab and F(ab').sub.2 are
attractive therapeutic formats when a short systemic half-life and
an effector-silent molecule are concurrently desired. Certain
fragments are also natural products of proteases associated with
invasive diseases such as tumor cells and bacteria and are
generated in an effort to evade immune surveillance. As a
consequence, the C-terminal neoepitope of the Fab and F(ab').sub.2
fragment is recognized by the immune system and result in AHA that
can provide surrogate Fc.
[0152] In this study, the reactivity of pre-existing AHA towards
the individual C-terminal residues spanning the upper hinge region
of human IgG1, IgG2 and IgG4 isotype was dissected. While it was
previously reported that pre-existing AHA did not exist towards
neoepitopes in the lower hinge of IdeS-cleaved human IgG2
antibodies, reactivity towards the upper hinge of human isotypes
was incompletely investigated so far. In this study, pre-existing
AHA towards the upper hinge of IgG2 and IgG4 isotype was not
detected. This in turn may suggest that these isotypes are not the
target of proteases of invasive diseases. This can be explained by
the effector-attenuated nature of these isotypes and the fact that
removing the Fc region of these isotypes does not provide an
advantage for tumors and bacteria. In contrast, IgG1 isotype seems
to be the prime target for these proteases. Indeed, several
proteases have been described to cleave in the upper hinge of human
IgG1, including plasmin, human neutrophil elastase and LysC. This
study shows that pre-existing AHA exist towards all cleavage sites
of the upper hinge of human IgG1 with the exception of D.sub.221.
Without being limited to a particular theory, the absence of AHA
toward D.sub.221 may be a reflection of the inability of human
proteases to cleave after this residue or the inability to raise
antibodies toward this neoepitope. The highest reactivity was
observed towards the C-terminal T.sub.223 Fab. Interestingly, this
C-terminus coincides with the cleavage point of human neutrophil
elastase, a protease that is secreted by neutrophils and
macrophages during inflammation to destroy bacteria and host tissue
(29).
[0153] Pre-existing AHA can rapidly recruit effector-function to a
molecule that is designed to be effector-less. Using a Fab of IgG2
or IgG4 isotype can provide one strategy to supply a molecule
without pre-existing antibody response. Alternatively, introducing
a non-natural residue at the heavy chain C-terminus, like the
T.sub.225L mutation, or truncating the upper hinge to D.sub.221 is
a strategy for the IgG1 isotype. While the T.sub.225L mutation
eliminates the response towards pre-existing AHA, it implies that
in principle, it can elicit an immune response as well. This is
further supported by a recent study with an anti-TNFR1 domain
antibody (34). The addition of a C-terminal alanine was sufficient
to reduce binding of pre-existing human anti-V.sub.H antibodies
during screening in vitro; however, one subject was found to
develop high levels of antibodies specific toward the modified
C-terminus in a Phase I clinical trial. In addition, potential
exopeptidase activity on a longer tail can eventually result in a
neoepitope that is recognized by pre-existing AHA. Removing the
unstructured upper hinge altogether like the Fab-D.sub.221 further
minimizes the risk of such secondary responses. This is supported
by the crystal structure of an anti-hinge antibody that has been
crystalized in complex with a peptide spanning the IdeS-cleaved
lower hinge of human IgG1 (30). The peptide is bound to the
antibody in an extended conformation, suggesting that truncating
the upper or lower hinge can successfully remove the neoepitope and
suppress an immune response for antibodies against the hinge
region.
[0154] These findings can also have implications on the design of
studies in cynomolgus monkeys. While the lower hinge region is
highly conserved between cynomolgus and human IgG, considerable
differences exist in the upper hinge region (31) that will prevent
cross-species reactivity. This may have an impact on toxicological
studies in cynomolgus as liabilities from pre-existing AHA towards
a human Fab cannot be addressed by these studies.
[0155] Beyond therapeutic use, the Fab-D.sub.221 can also be
considered for the recombinant expression of Fab for
crystallographic studies, since the upper hinge is not commonly
resolved in crystal structures due to the unstructured nature. This
example demonstrates that equal stability and expression can be
achieved with a Fab-D.sub.221 construct. Eliminating the
unstructured areas may further improve crystallization
outcomes.
[0156] The most efficient route to generate F(ab').sub.2 molecules
so far is by proteolytic digest and proteases with high-specificity
such as IdeS are preferred. As discussed earlier, pre-existing AHA
also exist towards the lower hinge of F(ab').sub.2 molecules. The
AHA titer towards IdeS-cleaved antibody is higher compared to a
Fab. Without being limited to a particular theory, this may be due
to the bivalent nature of the F(ab').sub.2 that provides an avidity
based binding component in the assay or a natural higher abundance
of F(ab').sub.2 that lead to increased titers. Several strategies
were employed to remove the AHA reactivity while maintaining
cleavage efficiency by IdeS.
[0157] Since the C-terminal residue has an important role in
epitope recognition (22), the first strategy was to mutate the
C-terminal residue of the F(ab').sub.2 to remove binding activity
of AHA. However, this was not possible due to the strict
requirement of glycine in the P1-position for efficient cleavage by
IdeS. The selected set of mutations in the P2-site had only modest
impact on AHA binding, further confirming the importance of the
C-terminal residue for reactivity with AHA. The coinciding
differences in AHA binding with the IdeS cleavage efficiency of the
P1 and P2 variants perhaps explains the reason why the IgG2 isotype
with valine in P2 and alanine in P1 position is less susceptible to
anti-hinge antibody response. The requirement for glycine in
position P1 for efficient cleavage is accompanied by the high
conservation of this residue within different isotypes and across
species.
[0158] By deleting three residues in the lower hinge (.DELTA.P456),
it was able to maintain the cleavage efficiency of IdeS while
removing pre-existing AHA recognition. It demonstrates that
positions upstream of the P3 site have minor relevance for
efficient cleavage. In addition to removing the reactivity towards
pre-existing AHA, truncating the lower hinge can dampen an immune
response towards this epitope. Based on structural studies, an AHA
binds the lower hinge in an extended conformation and the five
C-terminal residues interact with the antibody complementarity
determining regions (CDR) (30). By removing three residues from the
lower hinge, only 4 residues remained after IdeS cleavage. This
short sequence may not be sufficient for a robust immune response
and may reduce the likelihood of developing de novo antibodies
toward the engineered hinge.
[0159] Pre-existing antibodies have also been demonstrated to
decrease effector-function (32) in vitro and can also confound
immunogenicity assays during drug development. While the majority
of anti-therapeutic antibodies (ATAs) towards a humanized antibody
are targeting the idiotype, rheumatoid factor, a low affinity
antibody towards the Fc region has been described. One way to
eliminate artifacts by rheumatoid factor in the immunogenicity
assay is to use an antibody fragment devoid of the Fc region.
However, it is import to use fragments that are not recognized by
other pre-existing antibodies. These findings provide multiple Fab
formats and a F(ab').sub.2 format that can fulfill these
criteria.
[0160] In summary, by choosing the appropriate antibody fragment,
it is possible to evade recognition by pre-existing AHA. For Fab
molecules, several options exist: (1) using an IgG2 or IgG4
isotype, (2) a mutation of the C-terminal residue (T225L), or (3)
terminating the Fab with residue D.sub.221. Options are more
limited for F(ab').sub.2 molecules due to the need for proteolytic
digestion. A deletion was identified in the lower hinge of IgG1,
however, that maintains high cleavage efficiency and specificity
and removes reactivity with pre-existing AHA. Using these formats
can enable further minimization of safety concerns with antibody
fragments in a therapeutic setting and remove interference in assay
development.
Example 2
F(ab).sub.2 A1.sup.3456 has Reduced AHA Mediated Fc.gamma.RIIIa and
C1q Binding
[0161] It has been previously described that purified AHA
antibodies can act as surrogate Fc and restore ADCC/CDC function
that was lost by IdeS generated F(ab').sub.2 (20, 22). To study if
the reduced binding of AHA by the disclosed engineered Fab and
F(ab').sub.2 variants is further reflected by reduced recruitment
of Fc.gamma.receptors and C1q, bridging experiments were employed.
To assess binding of AHA to Fc.gamma.RIIIa, human serum was added
to Fab or F(ab').sub.2 coated wells and incubated for 2 hours as
described above. After the plates were washed, soluble
Fc.gamma.RIIIa(V158)-His-GST (consisting of the extracellular
domain fused with Gly-His6-glutathione-S-transferase ("Gly-His6"
disclosed as SEQ ID NO: 28) at the carboxy-terminus) was added at
0.5 .mu.g/ml. Bound Fc.gamma.RIIIa(V158)-His-GST was detected using
horseradish peroxidase-conjugated mouse anti-His antibody
(Penta-His (SEQ ID NO: 29), Qiagen, Germantown, Md.) followed by
TMB as the substrate. To assess binding of AHA to human C1q, human
serum was added to Fab or F(ab').sub.2 coated wells and incubated
for 2 hours as described above. After the plates were washed,
purified human C1q (Quidel, San Diego, Calif.) was added. Bound C1q
was detected with goat anti-C1q antibody (Nordic Immunological
Laboratories, Tilburg, The Netherlands) followed by rabbit
anti-goat IgG -HRP (Jackson ImmunoResearch, West Grove, Pa.) and
TMB as the substrate.
[0162] Significant binding of Fc.gamma.RIIIa and C1q for
F(ab').sub.2 was observed while little signal was detected for the
.DELTA.P456 F(ab').sub.2 variant, indicating that the engineering
of the F(ab').sub.2 variant significantly reduced the risk of
ADCC/CDC activation. The OD readings (n=3) were 0.45.+-.0.05,
0.10.+-.0.02 and 0.09.+-.0.02 for Fc.gamma.RIIIa binding and
0.98.+-.0.09, 0.158.+-.0.004 and 0.107.+-.0.009 for C1q binding on
F(ab').sub.2, .DELTA.P456 variant, and uncoated wells at 1:10
diluted serum, respectively.
IV. REFERENCES
[0163] 1. Desjarlais, J. R., and Lazar, G. A. (2011) Modulation of
antibody effector function. Experimental Cell Research. 317,
1278-1285.
[0164] 2. Olafsen, T. (2012) Fc engineering: serum half-life
modulation through FcRn binding. Methods Mol Biol. 907,
537-556.
[0165] 3. Gadkar, K., Pastuskovas, C. V., Le Couter, J. E.,
Elliott, J. M., Zhang, J., Lee, C. V., Sanowar, S., Fuh, G., Kim,
H. S., Lombana, T. N., Spiess, C., Nakamura, M., Hass, P., Shatz,
W., Meng, Y. G., and Scheer, J. M. (2015) Design and
Pharmacokinetic Characterization of Novel Antibody Formats for
Ocular Therapeutics. Invest. Ophthalmol. Vis. Sci. 56,
5390-5400.
[0166] 4. Walsh, G. (2014) Biopharmaceutical benchmarks 2014. Nat
Biotechnol. 32, 992-1000.
[0167] 5. Curtis, B. R., Swyers, J., Divgi, A., McFarland, J. G.,
and Aster, R. H. (2002) Thrombocytopenia after second exposure to
abciximab is caused by antibodies that recognize abciximab-coated
platelets. Blood. 99, 2054-2059.
[0168] 6. Porter, R. R. (1950) The formation of a specific
inhibitor by hydrolysis of rabbit antiovalbumin. Biochem 1 46,
479-484.
[0169] 7. Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H.
W., McKay, P., de Vos, A. M., and Lowman, H. B. (1999) Selection
and analysis of an optimized anti-VEGF antibody: crystal structure
of an affinity-matured fab in complex with antigen. J Mol Biol.
293, 865-881.
[0170] 8. Spiess, C., Zhai, Q., and Carter, P. J. (2015)
Alternative molecular formats and therapeutic applications for
bispecific antibodies. Mol. Immunol. 67, 95-106.
[0171] 9. Carter, P., Kelley, R. F., Rodrigues, M. L., and
Snedecor, B. (1992) High level Escherichia coli expression and
production of a bivalent humanized antibody fragment. Nature.
10.1038/nbt0292-163.
[0172] 10. Kostelny, S. A., Cole, M. S., and Tso, J. Y. (1992)
Formation of a bispecific antibody by the use of leucine zippers. J
Immunol. 148, 1547-1553. 11. Glennie, M. J., McBride, H. M., Worth,
A. T., and Stevenson, G. T.
[0173] (1987) Preparation and performance of bispecific F(ab'
gamma)2 antibody containing thioether-linked Fab'' gamma fragments.
Jlmmunol. 139, 2367-2375.
[0174] 12. Ellerman, D., and Scheer, J. M. (2011) Generation of
bispecific antibodies by chemical conjugation (Kontermann, R. E.
ed), pp. 47-63, Springer-Verlag Berlin Heidelberg,
10.1007/978-3-642-20910-9_3.
[0175] 13. Brerski, R. J., and Jordan, R. E. (2010) Cleavage of
IgGs by proteases associated with invasive diseases: an evasion
tactic against host immunity? MAbs. 2, 212-220.
[0176] 14. Nisonoff, A., Wissler, F. C., and Lipman, L. N. (1960)
Properties of the major component of a peptic digest of rabbit
antibody. Science. 132, 1770-1771.
[0177] 15. Pawel-Rammingen, von, U., Johansson, B. P., and Bjorck,
L. (2002) IdeS, a novel streptococcal cysteine proteinase with
unique specificity for immunoglobulin G. EMBO J. 21, 1607-1615.
[0178] 16. Vincents, B., Pawel-Rammingen, von, U., Bjorck, L., and
Abrahamson, M. (2004) Enzymatic characterization of the
streptococcal endopeptidase, IdeS, reveals that it is a cysteine
protease with strict specificity for IgG cleavage due to exosite
binding. Biochemistry. 43, 15540-15549.
[0179] 17. Osterland, C. K., Harboe, M., and Kunkel, H. G. (1963)
Anti-gamma-globulin factors in human sera revealed by enzymatic
splitting of anti-Rh antibodies. Vox Sang. 8, 133-152.
[0180] 18. Mellbye, O. J., and Natvig, J. B. (1971) Evidence for
immune complexes containing antibody to the pepsin site of IgG in
rheumatoid synovial fluids. Clin Exp Immunol. 8, 889-899.
[0181] 19. Terness, P., Kohl, I., Hubener, G., Battistutta, R.,
Moroder, L., Welschof, M., Dufter, C., Finger, M., Hain, C., and
Jung, M. (1995) The natural human IgG anti-F(ab').sub.2 antibody
recognizes a conformational IgG1 hinge epitope. J Immunol. 154,
6446-6452.
[0182] 20. Brerski, R. J., Luongo, J. L., Petrone, D., Ryan, M. H.,
Zhong, D., Tam, S. H., Schmidt, A. P., Kruszynski, M., Whitaker, B.
P., Knight, D. M., and Jordan, R. E. (2008) Human anti-IgG1 hinge
autoantibodies reconstitute the effector functions of
proteolytically inactivated IgGs. J Immunol. 181, 3183-3192.
[0183] 21. Rispens, T., de Vrieze, H., de Groot, E., Wouters, D.,
Stapel, S., Wolbink, G. J., and Aarden, L. A. (2012) Antibodies to
constant domains of therapeutic monoclonal antibodies: anti-hinge
antibodies in immunogenicity testing. J Immunol Methods. 375,
93-99.
[0184] 22. Brerski, R. J., Kinder, M., Grugan, K. D., Soring, K.
L., Carton, J., Greenplate, A. R., Petley, T., Capaldi, D.,
Brosnan, K., Emmell, E., Watson, S., and Jordan, R. E. (2014) A
monoclonal antibody against hinge-cleaved IgG restores effector
function to proteolytically-inactivated IgGs in vitro and in vivo.
MAbs.
[0185] 23. Simmons, L. C., Reilly, D., Klimowski, L., Raju, T. S.,
Meng, G., Sims, P., Hong, K., Shields, R. L., Damico, L. A.,
Rancatore, P., and Yansura, D. G. (2002) Expression of full-length
immunoglobulins in Escherichia coli: rapid and efficient production
of aglycosylated antibodies. J Immunol Methods. 263, 133-147
[0186] 24. Eaton, D. L., Wood, W. I., Eaton, D., Hass, P. E.,
Hollingshead, P., Wion, K., Mather, J., Lawn, R. M., Vehar, G. A.,
and Gorman, C. (1986) Construction and characterization of an
active factor VIII variant lacking the central one-third of the
molecule. Biochemistry. 25, 8343-8347.
[0187] 25. Wong, A. W., Baginski, T. K., and Reilly, D. E. (2010)
Enhancement of DNA uptake in FUT8-deleted CHO cells for transient
production of afucosylated antibodies. Biotechnol Bioeng. 106,
751-763.
[0188] 26. Bos, A. B., Duque, J. N., Bhakta, S., Farahi, F.,
Chirdon, L. A., Junutula, J. R., Harms, P. D., and Wong, A. W.
(2014) Development of a semi-automated high throughput transient
transfection system. Journal of Biotechnology. 180, 10-16.
[0189] 27. Van Schie, K. A., Wolbink, G.-J., and Rispens, T. (2015)
Cross-reactive and pre-existing antibodies to therapeutic
antibodies-Effects on treatment and immunogenicity. MAbs. 7,
662-671.
[0190] 28. Brerski, R. J., Oberholtzer, A., Strake, B., and Jordan,
R. E. (2011) The in vitro resistance of IgG2 to proteolytic attack
concurs with a comparative paucity of autoantibodies against
peptide analogs of the IgG2 hinge. MAbs. 3, 558-567.
[0191] 29. Belaaouaj, A., Kim, K. S., and Shapiro, S. D. (2000)
Degradation of outer membrane protein A in Escherichia coli killing
by neutrophil elastase. Science. 289, 1185-1188
[0192] 30. Malia, T. J., Teplyakov, A., Brerski, R. J., Luo, J.,
Kinder, M., Sweet, R. W., Almagro, J. C., Jordan, R. E., and
Gilliland, G. L. (2014) Structure and specificity of an antibody
targeting a proteolytically cleaved IgG hinge. Proteins.
10.1002/prot.24545.
[0193] 31. Jacobsen, F. W., Padaki, R., Morris, A. E., Aldrich, T.
L., Armitage, R. J., Allen, M. J., Lavallee, J. C., and Arora, T.
(2011) Molecular and Functional Characterization of Cynomolgus
Monkey IgG Subclasses. J Immunol. 186, 341-349.
[0194] 32. Jones, J. D., Shyu, I., Newkirk, M. M., and Rigby, W. F.
C. (2013) A rheumatoid factor paradox: inhibition of rituximab
effector function. Arthritis Res. Ther. 15, R20.
[0195] 33. Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S.,
Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek,
E. M., Kamphuisen, P. W., Kreuzer, J., Levy, J. H., Sellke, F. W.,
Stangier, J., Steiner, T., Wang, B., Kam, C.-W., and Weitz, J. I.
(2015) Idarucizumab for Dabigatran Reversal. N. Engl. J. Med. 373,
511-520.
[0196] 34. Cordy, J. C., Morley, P. J., Wright, T. J., Birchler, M.
A., Lewis, A. P., Emmins, R., Chen, Y. Z., Powley, W. M., Bareille,
P. J., Wilson, R., Tonkyn, J., Bayliffe, A. I., and Lazaar, A. L.
(2015) Specificity of human anti-variable heavy (VH) chain
autoantibodies and impact on the design and clinical testing of a
VH domain antibody antagonist of TNF-.alpha. receptor 1. Clin Exp
Immunol. 10.1111/cei.12680.
[0197] Although the foregoing compositions and methods have been
described in some detail by way of illustration and example for
purposes of clarity of understanding, the descriptions and examples
should not be construed as limiting the scope of the instant
disclosure. The disclosures of all patent and scientific literature
cited herein are expressly incorporated in their entirety by
reference.
Sequence CWU 1
1
591108PRTArtificial Sequencesource/note="Description of Artificial
Sequence Synthetic polypeptide" 1Ala Ser Thr Lys Gly Pro Ser Val
Phe Pro Leu Ala Pro Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala
Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70 75 80Tyr Ile
Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Lys
Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr 100
1052108PRTArtificial Sequencesource/note="Description of Artificial
Sequence Synthetic polypeptide" 2Ala Ser Thr Lys Gly Pro Ser Val
Phe Pro Leu Ala Pro Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala
Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70 75 80Tyr Ile
Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Lys
Val Glu Pro Lys Ser Cys Asp Lys Thr His Leu 100
1053107PRTArtificial Sequencesource/note="Description of Artificial
Sequence Synthetic polypeptide" 3Ala Ser Thr Lys Gly Pro Ser Val
Phe Pro Leu Ala Pro Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala
Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70 75 80Tyr Ile
Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Lys
Val Glu Pro Lys Ser Cys Asp Lys Thr His 100 1054106PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
polypeptide" 4Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser
Ser Ser Leu Gly Thr Gln Thr65 70 75 80Tyr Ile Cys Asn Val Asn His
Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Lys Val Glu Pro Lys Ser
Cys Asp Lys Thr 100 1055105PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
polypeptide" 5Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser
Ser Ser Leu Gly Thr Gln Thr65 70 75 80Tyr Ile Cys Asn Val Asn His
Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Lys Val Glu Pro Lys Ser
Cys Asp Lys 100 1056104PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
polypeptide" 6Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser
Ser Ser Leu Gly Thr Gln Thr65 70 75 80Tyr Ile Cys Asn Val Asn His
Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Lys Val Glu Pro Lys Ser
Cys Asp 1007101PRTArtificial Sequencesource/note="Description of
Artificial Sequence Synthetic polypeptide" 7Ala Ser Thr Lys Gly Pro
Ser Val Phe Pro Leu Ala Pro Cys Ser Arg1 5 10 15Ser Thr Ser Glu Ser
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val His
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser
Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr65 70 75
80Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95Thr Val Glu Arg Lys 1008105PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
polypeptide" 8Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
Cys Ser Arg1 5 10 15Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser
Ser Ser Leu Gly Thr Lys Thr65 70 75 80Tyr Thr Cys Asn Val Asp His
Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Arg Val Glu Ser Lys Tyr
Gly Pro Pro 100 1059103PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
polypeptide" 9Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
Cys Ser Arg1 5 10 15Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser
Ser Ser Leu Gly Thr Lys Thr65 70 75 80Tyr Thr Cys Asn Val Asp His
Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Arg Val Glu Ser Lys Tyr
Gly 10010104PRTArtificial Sequencesource/note="Description of
Artificial Sequence Synthetic polypeptide" 10Ala Ser Thr Lys Gly
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg1 5 10 15Ser Thr Ser Glu
Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val
His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr65 70 75
80Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95Arg Val Glu Ser Lys Tyr Gly Pro 10011105PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
polypeptide" 11Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
Cys Ser Arg1 5 10 15Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser
Ser Ser Leu Gly Thr Lys Thr65 70 75 80Tyr Thr Cys Asn Val Asp His
Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Arg Val Glu Ser Lys Tyr
Gly Pro Pro 100 10512102PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
polypeptide" 12Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
Cys Ser Arg1 5 10 15Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser
Ser Ser Leu Gly Thr Lys Thr65 70 75 80Tyr Thr Cys Asn Val Asp His
Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Arg Val Glu Ser Lys Tyr
10013101PRTArtificial Sequencesource/note="Description of
Artificial Sequence Synthetic polypeptide" 13Ala Ser Thr Lys Gly
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg1 5 10 15Ser Thr Ser Glu
Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val
His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr65 70 75
80Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95Arg Val Glu Ser Lys 100146PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 14Cys Asp Lys Thr His Thr1 5156PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 15Cys Asp Lys Thr His Leu1 5165PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 16Cys Asp Lys Thr His1 5174PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 17Cys Asp Lys Thr1185PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 18Lys Tyr Gly Pro Pro1 5194PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 19Lys Tyr Gly Pro1205PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 20Asp Lys Thr His Leu1 5215PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 21Asp Lys Thr His Thr1 52210PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 22Glu Pro Lys Ser Cys Asp Lys Thr His Thr1 5
10234PRTArtificial Sequencesource/note="Description of Artificial
Sequence Synthetic peptide" 23Cys Pro Pro Cys1249PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 24Pro Ala Pro Glu Leu Leu Gly Gly Pro1 5256PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide"MOD_RES(6)..(6)Any amino acid except Thr 25Cys Asp Lys Thr
His Xaa1 5264PRTArtificial Sequencesource/note="Description of
Artificial Sequence Synthetic peptide" 26Val Glu Arg
Lys1274PRTArtificial Sequencesource/note="Description of Artificial
Sequence Synthetic peptide" 27Asp Lys Thr His1287PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 28Gly His His His His His His1 5295PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 29His His His His His1 53011PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 30Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly1 5
103115PRTHomo sapiens 31Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
Gly Pro Ser Val1 5 10 153214PRTHomo sapiens 32Cys Pro Pro Cys Pro
Ala Pro Pro Val Ala Gly Pro Ser Val1 5 103315PRTHomo sapiens 33Cys
Pro Arg Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val1 5 10
153415PRTHomo sapiens 34Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly
Gly Pro Ser Val1 5 10 153523PRTHomo sapiens 35Lys Val Glu Pro Lys
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys1 5 10 15Pro Ala Pro Glu
Leu Leu Gly 203614PRTArtificial Sequencesource/note="Description of
Artificial Sequence Synthetic peptide" 36Cys Pro Pro Cys Pro Ala
Pro Glu Leu Gly Gly Pro Ser Val1 5 103714PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 37Cys Pro Pro Cys Pro Ala Pro Leu Leu Gly Gly Pro Ser Val1
5 103814PRTArtificial Sequencesource/note="Description of
Artificial Sequence Synthetic peptide" 38Cys Pro Pro Cys Pro Ala
Glu Leu Leu Gly Gly Pro Ser Val1 5 103913PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 39Cys Pro Pro Cys Pro Ala Pro Leu Gly Gly Pro Ser Val1 5
104013PRTArtificial Sequencesource/note="Description of Artificial
Sequence Synthetic peptide" 40Cys Pro Pro Cys Pro Ala Leu Leu Gly
Gly Pro Ser Val1 5 104112PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 41Cys Pro Pro Cys Pro Leu Leu Gly Gly Pro Ser Val1 5
104211PRTArtificial Sequencesource/note="Description of Artificial
Sequence Synthetic peptide" 42Cys Pro Pro Cys Leu Leu Gly Gly Pro
Ser Val1 5 104323PRTHomo sapiens 43Glu Pro Lys Ser Cys Asp Lys Thr
His Thr Cys Pro Pro Cys Pro Ala1 5 10 15Pro Glu Leu Leu Gly Gly Pro
204426PRTMacaca fascicularis 44Glu Ile Lys Thr Cys Gly Gly Gly Ser
Lys Pro Pro Thr Cys Pro Pro1 5 10 15Cys Pro Ala Pro Glu Leu Leu Gly
Gly Pro 20 254526PRTMacaca mulatta 45Glu Ile Lys Thr Cys Gly Gly
Gly Ser Lys Pro Pro Thr Cys Pro Pro1 5 10 15Cys Pro Ala Pro Glu Leu
Leu Gly Gly Pro 20 254619PRTHomo sapiens 46Glu Arg Lys Cys Cys Val
Glu Cys Pro Pro Cys Pro Pro Pro Pro Val1 5 10 15Ala Gly
Pro4719PRTMacaca fascicularis 47Gly Leu Pro Cys Arg Ser Thr Cys Pro
Pro Cys Pro Ala Glu Leu Leu1 5 10 15Gly Gly Pro4819PRTMacaca
mulatta 48Gly Leu Pro Cys Arg Ser Thr Cys Pro Pro Cys Pro Ala Glu
Leu Leu1 5 10 15Gly Gly Pro4967PRTHomo sapiens 49Glu Leu Lys Thr
Pro Leu Gly Asp Thr Thr His Thr Cys Pro Glu Pro1 5 10 15Lys Ser Cys
Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro Glu Pro Lys 20 25 30Ser Cys
Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro Glu Pro Lys Ser 35 40 45Cys
Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro Ala Pro Glu Leu Leu 50 55
60Gly Gly Pro655025PRTMacaca fascicularis 50Glu Phe Thr Arg Pro Cys
Asp Asp Thr Thr Pro Pro Cys Pro Pro Cys1 5 10 15Pro Ala Pro Glu Leu
Leu Gly Gly Pro 20 255125PRTMacaca mulatta 51Glu Phe Thr Pro Pro
Cys Gly Asp Thr Thr Pro Pro Cys Pro Pro Cys1 5 10 15Pro Ala Pro Glu
Leu Leu Gly Gly Pro 20 255220PRTHomo sapiens 52Glu Ser Lys Tyr Gly
Pro Pro Cys Pro Ser Cys Pro
Ala Pro Glu Phe1 5 10 15Leu Gly Gly Pro 205318PRTMacaca
fascicularis 53Glu Phe Thr Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu
Leu Leu Gly1 5 10 15Gly Pro5418PRTMacaca mulatta 54Glu Phe Thr Pro
Pro Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly1 5 10 15Gly
Pro5570PRTHomo sapiens 55Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr
His Thr Cys Pro Arg Cys1 5 10 15Pro Glu Pro Lys Ser Cys Asp Thr Pro
Pro Pro Cys Pro Arg Cys Pro 20 25 30Glu Pro Lys Ser Cys Asp Thr Pro
Pro Pro Cys Pro Arg Cys Pro Glu 35 40 45Pro Lys Ser Cys Asp Thr Pro
Pro Pro Cys Pro Arg Cys Pro Ala Pro 50 55 60Glu Leu Leu Gly Gly
Pro65 705616PRTHomo sapiens 56Thr Cys Pro Pro Cys Pro Ala Pro Glu
Leu Leu Gly Gly Pro Ser Val1 5 10 155713PRTArtificial
Sequencesource/note="Description of Artificial Sequence Synthetic
peptide" 57Thr Cys Pro Pro Cys Pro Leu Leu Gly Gly Pro Ser Val1 5
105812PRTArtificial Sequencesource/note="Description of Artificial
Sequence Synthetic peptide" 58Thr Cys Pro Pro Cys Leu Leu Gly Gly
Pro Ser Val1 5 105914PRTArtificial Sequencesource/note="Description
of Artificial Sequence Synthetic peptide" 59Cys Pro Pro Cys Pro Ala
Pro Pro Val Ala Gly Pro Ser Val1 5 10
* * * * *